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ABSTRACT
A bacterial type I toxin-antitoxin system contains two genes: one encodes a small toxic
protein and the second, a small regulatory RNA (sRNA) that inhibits toxin production. To date,
very few type I loci have been described thoroughly in regards to the regulation of toxin and the
function of the toxin at endogenous levels. In this study, I demonstrated that the zor-orz locus of
Escherichia coli O157:H7 is composed of two highly homologous type I toxin-antitoxin systems:
zorO-orzO and zorP-orzP. The zor genes encode the toxins and the orz genes encode the antitoxin
sRNAs. Overexpression of zorO is toxic to E. coli and causes bacterial growth stasis or cell death;
however, co-expression of orzO neutralizes this toxicity and restores normal bacterial growth.
Rapid membrane depolarization was observed upon ZorO overproduction, suggesting that ZorO
targets the membrane. Replacement of two charged amino acids in ZorO, glutamic acid at the 16th
position and arginine at the 23rd position, can impair ZorO toxicity.
Given its inherent toxicity, production of ZorO is tightly controlled by both its 5’
untranslated region (UTR) and the antitoxin OrzO. The zorO 5’ UTR harbors two distinct regions
that modulate zorO translation. One is a putative ribosome standby site that is exposed only upon
processing of the 5’ UTR and likely promotes translation by facilitating ribosome preloading onto
the mRNA. The other region spans from +35 to +50 of zorO and is required for optimal translation
of zorO, although the underlying mechanism remains unclear. The OrzO sRNA inhibits ZorO
production by reducing both the stability and the translation of the zorO mRNA. Specifically,
OrzO base pairs to the putative standby site of zorO and impedes translation, potentially through
competition with ribosome for this site. Successful base pairing of zorO by OrzO requires at least
15 nucleotides of perfect sequence complementarity. Once paired, the RNA duplex can be
degraded by RNase III, rendering the zorO mRNA untranslatable. Collectively, this multilayered
control of ZorO production limits its toxicity. Hence, my work provides new insights into
regulation of type I toxins by their antitoxin sRNAs and beyond the sRNAs.
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CHAPTER I

Introduction
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Publication note
A version of the section III (III. Biological roles of type I gene pairs), the table, and all figures of
this chapter was originally published by Jia Wen and Elizabeth M. Fozo:
Wen, J.; Fozo, E.M. sRNA Antitoxins: More than One Way to Repress a Toxin.
Toxins 2014, 6, 2310-2335.
My contribution to this paper was the literature review and shared writing with Dr.
Elizabeth Fozo.
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I. An overview of bacterial toxin-antitoxin systems
Toxin-antitoxin (TA) systems have been identified on plasmids and chromosomes of numerous
bacteria and archaea. In bacteria, these systems are involved in stress response [reviewed in (1)].
In response to different environmental stimuli, the TA systems can be activated and participate in
diverse cellular processes including DNA replication, macromolecular synthesis, membrane
disruption, phage infections, and cytoskeletal polymerization, therefore facilitating bacteria to
cope with the ever changing environment [reviewed in (2,3)]. Each TA locus is composed of a set
of two closely linked genes: one encodes a toxic protein whose overproduction leads to cell growth
stasis or cell death, and the other encodes an antitoxin that counteracts the effects of the toxin.
Depending on the nature of the antitoxin as well as the modes of action by which the antitoxin
represses the toxin, the TA systems can be classified into five types.
The type I TA system contains a stable toxin protein and a labile antitoxin small RNA
(sRNA). The antitoxin sRNA possesses sequence complementarity to the toxin mRNA that allows
it to base pair with the toxin mRNA. Base pairing by the sRNA can lead to degradation of the
mRNA and/or reduced translation of the mRNA, hence inhibiting toxin production.
In the type II system, both the toxin and the antitoxin are proteins. Most type II loci
identified to date are arranged in an operon with the antitoxin gene located upstream of the toxin
gene. Typically, the type II toxin functions as an endonuclease and the antitoxin neutralizes its
activity by binding with the toxin protein [reviewed in (4)]. In addition, transcription of the TA
operon can be autoregulated upon binding of the antitoxin or the antitoxin-toxin complex to the
promoter, adding another layer of regulation (5-7).
Like the type I system, the type III TA system also is comprised of a protein toxin and a
RNA antitoxin. However, repression by the antitoxin occurs through a distinct mechanism. The
type III antitoxin gene is composed of a stretch of short tandem repeats and separated from the
toxin gene by a weak terminator. Instead of base pairing to the toxin mRNA, the antitoxin RNA
forms pseudoknots and directly binds to the toxin protein, sequestering the protein thereby
blocking its activity (8). All type III TA systems identified to date are involved in phage resistance
by inducing premature bacterial cell death upon phage infection [reviewed in (9)].
The type IV TA system is composed of a protein toxin and a protein antitoxin. Unlike type
II loci, the toxin and the antitoxin of the type IV system do not directly interact. Rather, the
antitoxin counteracts the effects of the toxin by acting on the targets of the toxin. The cbtA/cbeA
3

gene pair of Escherichia coli is the sole member of this type. The CbtA toxin inhibits the
polymerization of the bacterial cytoskeletal proteins MreB and FtsZ. On the contrary, the antitoxin
CbeA protein directly interacts with MreB and FtsZ and promotes bundling of FtsZ and MreB
protofilaments, therefore enhancing polymerization (10).
To date, only one gene pair of the type V TA system has been identified. This type V gene
pair ghoT/ghoS was discovered in the chromosome of E. coli (11). The GhoT toxin is a membrane
lytic peptide whose overproduction causes ghost cell formation, whereas the antitoxin GhoS
protein is a RNase that specifically cleaves the ghoT mRNA and renders it untranslatable.
Bacteria can harbor multiple different types of TA loci. For instance, at least 33 TA loci
have been identified in lab strain E. coli K12 [reviewed in (3)]. Further, the pathogen
Mycobacterium tuberculosis has more than 60 TA loci, with many of the loci duplicated pairs
[reviewed in (12)]. Duplication of TA gene pairs is common, but it is not clear why bacteria may
possess redundant loci. Homologs of bacterial TA systems have also been discovered through
genome mining in many archaea (13). Additionally, BLAST searches against fungal genomes have
identified some toxin homologues (14). However, whether these homologues are functional and
whether their antitoxin counterparts are present have not been examined. Given the prevalence of
TA systems, it would be interesting to know what potential advantages the TA systems can provide
to organisms. This is particularly relevant with respect to evolution of the organisms across the
three domains of life.

II. Repression of the type I toxin by the antitoxin sRNA
The type I TA systems were initially identified on plasmids where they confer plasmid
maintenance through a post-segregational killing mechanism, as exemplified by the hok/sok of the
R1 plasmid of E. coli and the fst/RNAII of the pAD1 plasmid of Enterococcus faecalis (15-17).
Homologs of plasmid encoded type I TA systems as well as new type I loci have since been
discovered in numerous bacterial chromosomes. Most type I toxins identified to date are small
proteins that are less than 60 amino acids and contain one putative transmembrane domain. Owing
to their hydrophobic nature, these toxins are proposed to form pores in the bacterial cell membrane
and impair ATP synthesis, which eventually leads to cell growth stasis or cell death, similar to
phage holins [reviewed in (18)]. To avoid such detrimental effects caused by type I toxins, their
4

levels must be carefully controlled. One mechanism to modulate the production of a type I toxin
is through base pairing by its corresponding antitoxin sRNA.
Unlike the trans-encoded sRNAs that are located distal from their targets and act through
limited base pairing, the type I antitoxin sRNAs are encoded antisense to the toxin genes and share
extensive sequence complementarity with the toxin mRNAs [reviewed in (19)]. The genetic
organizations of the type I TA loci discussed in this section are listed in Table 1.1. Due to their
greater base pairing potential, most type I sRNAs can repress their cognate toxin mRNAs without
the protein Hfq, a RNA chaperone required for the function of many identified trans-encoded
sRNAs.
For some pairs, base pairing between the antitoxin sRNA and the toxin mRNA happens in
a stepwise fashion: there is an initial contact between single-stranded regions of each RNA, then
extends to the flanking sequences of the complimentary region or stimulates binding through other
distal portions of the RNAs [reviewed in (9)]. This has been demonstrated by the ibsC/sibC type I
locus in E. coli (20). The SibC sRNA first interacts with the ibsC mRNA through two isolated
complimentary regions, TRD1 and TRD2. The base pairing then extends to the flanking region
and leading to pairing of over 70 nt. Another more complicated example is the type I locus
fst/RNAII. In this case, the RNAII sRNA possesses three distinct regions of complementarity to
the fst mRNA: a 3’ termination loop region that can base pair to the 3’ end of fst, and two 5’ direct
repeats, DRa and DRb, that can base pair to the 5’ end of the fst (21). Base pairing initiates via
interactions between the complementary regions in the 3’ terminator loops of both RNAs, resulting
in the formation of a “kissing complex”. This brings the 5’ ends of the RNAII sRNA and the fst
mRNA close to each other, which subsequently promotes a second base pairing event through the
two direct repeats on RNAII and the corresponding sites at the 5’ fst (22). Afterwards, the base
pairing progresses to the complementary region in between the DRa and DRb sites, forming a
stable fst-RNAII duplex.
Given the extensive base pairing between the sRNA and the toxin mRNA, one would
imagine that base pairing will result in structural changes of both RNAs, as the previously
structured complimentary sequences are now “occupied”. Depending on whether the ribosome
binding site (RBS) structure is involved, the effects of such structural changes may vary. In the
type I pair bsrG/sr4 of Bacillus subtilis, binding by SR4 sRNA to the 3’ end of the bsrG mRNA
leads to structural rearrangement of the bsrG RBS (Figure 1.1) (23). More specifically, the bsrG
5

RBS is located in a 4 nt-long stem and the upstream sequences of this stem are originally paired
with part of the bsrG complementary region. Upon SR4 base pairing, the complementary region
on bsrG is occupied, therefore releasing the sequences upstream of the RBS-containing stem. This
leads to a structural rearrangement and pairing such that the length of the RBS-containing stem
extends to 8 nt. The increased stem length was shown to impede translation, therefore preventing
BsrG toxin production. To date, SR4 sRNA is the only type I antitoxin that base pairs to the 3’ end
of the toxin mRNA but inhibits toxin translation through impacting the distal RBS structure.
Aside from affecting RNA structure at a distal region, a more common outcome of base
pairing seen in type I pairs is the interruption of ribosome binding to the “local” mRNA. This
typically leads to impaired translation of the toxin mRNA; however, the detailed mechanisms can
vary depending on where base pairing occurs. Some type I antitoxin sRNAs base pair over the
translation initiation region (TIR) of the toxin mRNAs and block translation, as demonstrated by
the SymR sRNA of the symE/symR pair (24,25), the SibC sRNA of the ibsC/sibC pair (Figure 1.2)
(26), and the RalA sRNA of the ralR/ralA pair of E. coli (27). On the contrary, some type I
antitoxin do not interfere with the TIR of the toxin, but instead the TIR of a leader peptide. One
classic example is the hok/sok locus of the R1 plasmid (Figure 1.3) (15). The 5’ untranslated region
(UTR) of hok harbors a small open reading frame (ORF) termed mok whose translation is coupled
with hok (16). The Sok sRNA base pairs to the hok 5’ UTR but does not bind with its RBS. Rather,
it overlaps with the TIR as well as part of the coding region of mok, leading to translation inhibition
of both mok and hok. Similar to that of hok/sok, base pairing by the IstR-1 sRNA of the tisB/istR1 locus in E. coli also occurs at the 5’ UTR of tisB distal to the tisB RBS (28). However, regulation
of the TisB production mediated by the IstR-1 sRNA is conducted through a different mechanism
in that the sRNA blocks a ribosome standby site on the mRNA (Figure 1.4) (29). More specifically,
the tisB RBS is sequestered in a stem structure that prevents the ribosome from directly accessing
the RBS. Instead, the ribosome first preloads onto a standby site upstream of the RBS at the tisB
5’ UTR and then moves to the RBS when the RBS opens. This standby site is required for
translation and overlaps the region of base pairing for the IstR-1 sRNA. Therefore, base pairing of
IstR-1 to the standby site interferes with ribosome preloading, leading to translation inhibition of
tisB mRNA.
Regardless of where the base pairing occurs, it often induces degradation of the mRNA.
Typically, upon base pairing, the double-stranded specific RNase III cleaves the sRNA-mRNA
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duplex, rendering the mRNA untranslatable. For example, base pairing by the IstR-1 sRNA results
in a processed form of tisAB (+106 tisAB) that was proved to be translationally inactive (29).
Further, RNase III cleaves the bsrG toxin mRNA at the complementary region after bsrG is paired
with the SR4 antitoxin sRNA (30). In some cases, stimulating degradation of the toxin mRNA is
the main mechanism used by the antitoxin sRNA to inhibit toxin production, particularly when
base pairing by the sRNA solely occurs at the 3’ end of the toxin mRNA. One such example is the
txpA/ratA pair of B. subtilis, in which the RatA sRNA base pairs to the txpA mRNA at its 3’ end
resulting in a series of cleaved txpA transcripts that are subsequently degraded by PNPase (Figure
1.5) (31,32). In addition to txpA/ratA, three other type I loci in B. subtilis, the bsrE/SR5 and the
bsrH/as-bsrH, use the same strategy to modulate production of the toxin (32-34). It has been shown
that the loss of cell viability seen in B. subtilis upon RNase III encoding gene deletion is caused
by de-repression of two type I toxins including TxpA (32), which further reveals the essential role
of RNase III in regulating toxin production of these type I loci.
Although in many described type I loci the sRNA can stimulate toxin mRNA degradation,
two exceptions have been observed. One is the fst/RNAII pair in which the formation of the RNA
duplex greatly increases the stability of both RNAs: the half-life of fst mRNA showed a 1.6- to
2.2-fold increase and the half-life of RNAII increased from 4 min to 16 min (35). The other is the
pair ralR/ralA discovered on the rac prophage of E. coli. In this case, there was no substantial
reduction in ralR mRNA levels following interaction with RalA, as detected by qRT-PCR (27).
Interestingly, in both cases, the small RNA is located antisense to the 3’ end of toxin mRNA but
shares additional base pairing complementarity with the 5’ end of the toxin mRNA. As described
above, complete base paring between RNAII and fst occurs at both the 5’ end and the 3’ end of the
mRNA, whereas base pairing in most other type I systems occurs only at one end. Perhaps the
more extensive base pairing of fst/RNAII accounts for the resistance of the fst transcript to
degradation; however, more experimental evidence is needed to make such assumption. Another
fact worth noting is that the studies of fst/RNAII and ralR/ralA did not compare the stability of the
mRNA in a wild type versus a RNase III and/or other double-stranded specific RNases deficient
background. Therefore, it is possible that the RNase III dependent degradation still occurred, but
its effect was hidden by a greater increase of mRNA stability caused by formation of the RNA
duplex. It would be interesting to see how the half-life of fst or ralR changes upon RNase III
deletion.
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As mentioned in the previous section, for those instances where it has been examined, the
toxin mRNA is relatively stable whereas the antitoxin sRNA usually has a very short half-life. For
instance, the half-life of the hok mRNA of the hok/sok pair is ~ 30 minutes whereas the half-life
of Sok is ~ 30 seconds (36). This adds an additional layer to toxin repression given that despite
successful base pairing, the time window during which one sRNA is “alive” may be too short for
the sRNA to exert its inhibitory effects. So, how does antitoxin repress its toxin given this
shortcoming? it has been suggested that the antitoxin sRNA is in molar excess over the
corresponding toxin mRNA. In the aforementioned hok/sok pair encoded on the R1 plasmid, both
genes are constitutively expressed; however, the Sok is transcribed from a stronger promoter than
hok (37). Hence, hok is outnumbered by Sok as long as the R1 plasmid is present to generate Sok.
This compensates for the short half-life of Sok and allows successful repression of the hok mRNA.
Similar observations were shown in the chromosomally encoded type I pairs bsrG/sr4 and bsrE/sr5
in B. subtilis, in which the antitoxin promoters are far stronger than the toxin promoters (30,38).
Particularly, the stronger promoter of sr5 was shown to lead to a 7-8 folds higher levels of SR5
sRNA than the bsrE mRNA under normal growth conditions. In other cases, the difference in the
amount of the sRNA and the mRNA is due to transcriptional repression of the toxin, as is seen in
the chromosomally encoded loci tisB/istR-1 and symE/symR in E. coli. Both loci are involved in
SOS response and each toxin gene is subject to LexA repression (28,39). On the contrary, the istR1 or symR is constitutively transcribed, leading to repression of the corresponding toxin mRNA
(24).
To summarize, type I antitoxins repress the toxins production via base pairing, but the
direct outcomes of base pairing can vary. Base pairing can lead to translation inhibition of the toxin
mRNA and/or degradation of the toxin mRNA through several distinct mechanisms. Additional
regulation is conferred through differences in RNA stability and abundance throughout growth
conditions: although the sRNA is not as stable compared to the toxin mRNA, it is usually expressed
in excessive amount over the toxin mRNA, thereby rendering successful repression.

III. Biological roles of type I gene pairs
To date, numerous examples of type I loci have been described in bacterial chromosomes. However,
whether these chromosomal copies have a true biological function is still questioned. Given that
the first loci were described on plasmids and serve to stabilize plasmids, many assumed that these
8

loci are “selfish” DNA elements. Yet, bioinformatic analyses indicate that many toxin-antitoxin
pairs have no clear homology to mobile genetic elements nor is there evidence for horizontal gene
transfer (40). Also, many toxin gene sequences are highly conserved with strong predicted
ribosome binding sites and little evidence of sequence degeneration, suggesting that bacteria are
maintaining these genes. This would support the argument that, at least for some chromosomally
encoded loci, they do indeed possess a true biological function.
Plasmid remnants? The hok/sok locus of plasmid R1 was the first type I toxin-antitoxin gene pair
to be described. Upon cell division, if a daughter cell does not inherit a copy of the plasmid, the
unstable Sok antitoxin will be degraded, allowing the stable hok mRNA to be translated, and kill
the plasmid-less cell. Specifically, the Hok toxin oligomerizes in the inner membrane, causing pore
formation, and loss of viability (16). This is particularly evident with the appearance of “ghost” cells
upon Hok overproduction. Hok though appears to act internally as application of exogenous Hok
to cells could not induce cell killing; in fact, synthetic Hok could only kill cells if electroporated
into the cells (41). Combined, these data supported that the function of the plasmid encoded
hok/sok locus is to maintain the plasmid within the bacterial population.
With the advent of genomic sequencing, hok/sok loci were found within the genomes of
numerous E. coli strains and other Gram-negative bacteria; for some E. coli strains examined, there
are as many as 12 copies of the locus (40,42). In some instances, there is evidence of sequence
insertions or sequence degeneration, and it is likely that these loci no longer produce the toxin or
antitoxin. However, a large number appear to be intact and are potentially expressed (42). So, what
are these chromosomal copies doing? Are they simple remnants of past plasmids? Do they serve
to maintain plasmids within the population or maintain chromosomal stability in the population?
Given that there are numerous copies within a single species and some loci appear degenerate,
these questions are not trivial to address. Future work will hopefully resolve whether or not
chromosomally encoded hok/sok gene pairs have a true biological function.
Impairment of chromosomal structure As described above, the fst/RNA II locus of the pAD1
plasmid of E. faecalis confers plasmid addiction through post-segregational killing (17). Like Hok
and many other type I toxins, the Fst toxin also contains a putative transmembrane domain. When
overexpressed, it can cause cell membrane permeabilization and cessation of macromolecular
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synthesis (43). However, unlike Hok, overproduction of Fst does not result in the formation of
ghost cells [reviewed in (44)]. A recent study revealed that the Fst-resistant E. faecalis M7 strain
harbors a mutation in the rpoC gene encoding the β subunit of RNA polymerase (45). Normally,
an Fst-sensitive E. faecalis strain will induce the expression of a variety of membrane transporters
upon fst overexpression; however, the M7 strain did not. This suggested that Fst induces membrane
transporters and that induction may deplete the cell of energy. To validate this, the authors treated
wild type E. faecalis with reserpine, an inhibitor of transporters, and then induced fst in the treated
strain. Upon treatment with reserpine, wild E. faecalis survived Fst toxicity far better than without
(45). Thus, the induction of membrane transporters is a major cause of Fst-induced toxicity.
Intriguingly, Fst induced membrane damage occurs late upon Fst overproduction (46). This
indicated that the loss of membrane integrity may not be the primary effect of Fst toxin. Studies
have revealed that the primary effect of Fst overexpression is condensation of the nucleoid. The
effects on nucleoid structure have been observed not only in E. faecalis, but also Staphylococcus
aureus, B. subtilis, and E. coli; although how Fst disrupts nucleoid structure remains unclear
(43,46,47). Interestingly, bioinformatic analysis concluded that both Fst and Ldr, a chromosomally
encoded type I toxin of E. coli (26), are within the same toxin superfamily (40). Overexpression
of LdrD led to a similar nucleoid condensation in E. coli, suggesting that this is a conserved feature
for this family (26).
Like the hok/sok locus, numerous homologs to fst/RNAII have been identified in many
bacterial chromosomes (40,47). Given the above effects on membrane transportation upon Fst
overproduction, it is interesting to note that several chromosomal fst/RNAII loci are flanked by
transporters, specifically, carbohydrate transporters (47). Also, for those examined, both the toxin
and antitoxin are transcribed, indicative that they are likely functional. What their biological role
may be is not clear. For a homolog identified in Streptococcus mutans, described below, there are
links to persister cell formation (see below) (48). For a homolog found on the chromosome of E.
faecalis V583, deletion of the antitoxin component (RNAII) led to increased virulence in a mouse
model, though how fst could contribute to virulence is not known (49). It is important to note that
even very low levels of Fst production can lead to the formation of suppressors, so further
examination of this RNAII deletion strain is needed. Interestingly, a homolog of fst/RNAII in S.
aureus indicates that expression of the toxic peptide is induced upon cellular stress, suggesting
that it may have a role in responding to changing environments (50).
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Persister formation Although a bacterial population maybe genetically identical, cellular growth
and gene expression are not equivalent across the population of cells. A small portion of cells
within a population are non-growing or slow-growers; these “dormant” cells are termed persisters
(51,52). Given that most antibiotics target actively growing cells, persisters are often highly
antibiotic resistant (53). The tisB/istR-1 locus has been linked with persister formation.
Specifically, the antibiotic ciprofloxacin targets bacterial DNA gyrase, leading to DNA damage
and induction of the SOS response (54). The type I toxin gene tisB is induced by SOS damage
(28). Deletion of the entire tisB/istR1 locus in E. coli led to a decrease in persisters tolerant to
ciprofloxacin. Yet a strain deleted for only the antitoxin IstR-1 exhibited a 10- to 100-fold increase
in the level of persisters (55,56). This indicated that TisB, when expressed at its endogenous level,
plays an essential role in persister formation.
How then could a small hydrophobic protein lead to persister formation? A previous study
demonstrated that an epitope tagged version of TisB localized to the inner membrane of E. coli
(57). Additionally, work with synthetic TisB demonstrated that TisB monomers can rapidly and
spontaneously bind to membranes (58). It is thought that these monomers within the membrane
may form dimers that would allow protons to pass or alternatively that TisB monomers aggregate
to form pores that are selective for anions (59). Regardless, production of TisB and its insertion in
the membrane would cause a loss of proton motive force and a decline of intracellular ATP. This
was verified in vivo when, overproduction of TisB led to a dramatic loss of ATP within E. coli
within 5 minutes (57). Along with this, ciprofloxacin requires ATP for its function, thus expression
of TisB would cause a decrease in ATP levels leading to both an inhibition of macromolecule
synthesis and an inhibition of the antibiotic’s activity. To summarize, insertion of TisB into the
membrane would cause a loss in proton motive force, depletion of ATP levels for ciprofloxacin
activity and macromolecule synthesis, and the consequential increase in the number of persisters
within the population (55,56,60).
This consequential decrease in cellular metabolism caused by TisB is similar to what has
been reported for type II toxins. Type II toxin proteins are often “larger” (~100 amino acids) than
type I toxins and are not particularly hydrophobic. They have defined biochemical activities with
most examples functioning as either ribonucleases or inhibitors of DNA gyrase (61). It was
hypothesized that by induction of type II toxin activity (specifically ribonuclease activity), cellular
translation would be halted, giving rise to the “dormant” persister cell phenotype. This is supported
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by the observation that deletion of multiple type II toxin-antitoxin loci in E. coli reduced the level
of persisters (62). Further, a recent study utilizing chemical inhibitors of macromolecular synthesis
provided additional evidence: by decreasing macromolecular synthesis chemically, the frequency
of persister cell formation was far higher over control populations that were not treated (63). Thus,
type II toxins and TisB appear to induce persister formation by reducing cellular metabolism
through the inhibition of macromolecular synthesis. It is critical to note, however, that most
identified type I toxins have not been examined to conclude whether or not they participate in
persister formation, but such analysis would be of great interest.
The studies with TisB illustrate another important point: the critical balance of toxin levels
within a cell. Overproduction of TisB clearly causes cell death (28,57,64), yet in some instances,
it can lead to persister formation (55). In particular, analysis suggests that the expression of tisB is
induced 1000-fold under SOS conditions yet this does not induce cell killing (55,57). Thus, the
fine-tuning of toxin and antitoxin levels is critical for persister formation. When the toxin level is
below that of the antitoxin, the antitoxin successfully represses toxin expression, and the cell is
unharmed. If the toxin level is higher than that of the antitoxin, the toxin escapes repression and
impairs cell growth. Depending upon how excessive toxin levels are to the levels of the antitoxin
will determine whether the cell becomes dormant (i.e., persister) or is killed. When the levels of
the toxin and the antitoxin are close, some cells will have an imbalance in the ratio of toxin:
antitoxin. Owing to the stochastic nature of bacterial populations, this small portion of the
population will become persisters (65). The exact amounts of TisB needed to form ciprofloxacininduced persisters is currently not known but will be of great interest in understanding the balance
between the benefits and costs of possessing this toxic gene.
In the Gram-positive bacterium S. mutans, a homolog to the fst/RNAII locus of pAD1 has
been linked to persister cell formation (48). Deletion of this locus, known as Fst-Sm/srSm, did not
impact persister formation. However, the number of persisters was greatly reduced upon treatment
with cell-wall damaging antibiotics in a strain harboring the entire locus on a multicopy plasmid
(48). Unlike tisB, this observation appears to be due to increasing the number of Fst-Sm/srSm
copies within the cell; analysis has not revealed whether or not this observation can be attributed
either to the toxin, the antitoxin, or just increased copies of the entire locus. How then, would
increasing the number of copies of this locus lead to decreased persister cell formation? This could
be due again to levels of the toxin versus the antitoxin; by increasing the number of loci within the
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cell, there could be an imbalance in the ratio of toxin: antitoxin, leading to heighten cell killing
and decrease in persister formation. A detailed analysis of toxin and antitoxin RNA and toxin
protein levels across the cellular population will be needed to further conclude how this gene pair
impacts persister cell formation.
Chromosomal stabilization and recombination In B. subtilis, many of its predicted
chromosomally encoded type I loci are located within integrated mobile elements. For instance,
the txpA/ratA and bsrH/as-bsrH loci are located within the skin element (31,66,67), while bsrG/sr4
and yonT/as-yonT are within the SPβ prophage (30,40). Additionally, the newly identified bsrE/sr5
was found in the prophage-like region P6 (33). Overexpression of these toxin genes slows cell
growth or causes cell lysis, while deletion of these genes does not lead to noticeable consequences.
The presence of these gene pairs on mobile genetic elements suggests that they may
maintain these elements within the chromosome. This maintenance may then provide the cell with
a selective advantage under specific environmental conditions. For example, studies of the SPβ
prophage suggest that it contains genes that are beneficial to B. subtilis. The gene sspC encodes a
small acid-soluble protein that provides high UV light resistance to spores and is found on the SPβ
prophage (68). The gene nonA, examined in the SPβ prophage region of the B. subtilis Marburg
strain, encodes a protein that protects cells against infection from the bacteriophage SP10 (69).
Perhaps the two toxin-antitoxin loci then contribute to maintaining this element within the
population. Interestingly, the BsrG type I toxic protein that is encoded on the SPβ prophage is
temperature-sensitive. Rapid degradation of bsrG mRNA was observed at 48°C, indicating a
potential role of this toxin in response to changing temperatures (30).
However, some prophage regions may simply act as selfish elements in the chromosome.
One possible example for this theory is the skin element of B. subtilis. This large element (48 kb)
is located within the sigK gene encoding the RNA polymerase sigma factor σK (70). During
sporulation, skin is excised from the chromosome, creating an intact sigK gene. This excision only
occurs from the chromosome of the mother cell, and not from the chromosome of the forespore.
An engineered strain with the skin element deleted was able to grow and sporulate normally,
suggesting that this region does not play an essential role in viability or sporulation (70). Thus, is
skin simply a piece of selfish DNA? Within the skin are two different type I toxin-antitoxin loci:
txpA/ratA and bsrH/as-bsrH. Thus, if the skin is lost, expression of those toxins could be lethal for
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the cell, helping to maintain the element within the population. However, a study did identify genes
conferring arsenate and arsenite resistance within the skin element (71), implying that there are
genes of value to B. subtilis within this region. Perhaps a more detailed analysis of the genes
encoded with the skin element could determine if the function for txpA/ratA and bsrH/as-bsrH is
to maintain a “useful” piece of mobile DNA.
It is also possible that these type I modules of B. subtilis have functions other than
stabilizing the chromosomal regions. several type I toxin encoding genes, such as brsG, brsE and
brsH, have putative ResD response regulator binding sites upstream, indicating that their toxin
products may participate in response to oxygen limitation (34). Durand et al noted that the
described toxins and antitoxins are all under control of the vegetative sigma factor σA; thus all
could be quickly induced (34). Further analysis of the balance between the expression of the toxins
and antitoxins will provide much-needed evidence for their physiological roles.
In E. coli, the newly described dinQ/agrB locus may also play a role in chromosomal stability
(72). Transcription of the dinQ toxin, like tisB and symE, is also regulated by LexA, and is induced
upon DNA damage. Deletion of the antitoxin agrB led to elevated DinQ levels; however, this
deletion did not directly impact SOS activities. Instead, a strain deleted for agrB, had a 400-fold
reduction in recombination frequency, suggesting that DinQ interferes with recombination (72).
The small toxin is found in the membrane, and its overproduction can lead to decreased ATP
levels, like TisB, as well as increased nucleoid condensation, like Fst and LdrD. Further work to
elucidate how these phenotypes are linked to DinQ biochemical activity will be of great interest.
Inhibition of competitors The txpA/ratA homologous locus, sprG1/sprF1, in S. aureus was
recently described (73). Like the original txpA/ratA locus, the locus characterized was found on a
mobile genetic element, ΦSa3 PI, a phage integrated within the chromosome; however, additional
copies were predicted within the core genome (31,32,73). The sprG1 gene encodes two toxic
peptides from two in-frame initiation codons, and the sprF1 gene encodes an antitoxin sRNA.
Interestingly, we note that even the original member of this family, txpA of B. subtilis, may produce
two peptides [see (31)]. For S. aureus, overproduction of either the long or short SprG1 peptide
inhibited cell growth and caused cell death; however, co-expression of the SprF1 antitoxin could
repress toxicity induced by either toxic peptide (73). Both SprG1 peptides contain a putative
transmembrane domain and both proteins were detected in the supernatant. Given this, the authors
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investigated whether or not external addition of either peptide could be toxic to cells. Application
of synthetic forms of SprG1 inhibited the growth of E. coli, Pseudomonas aeruginosa and S.
aureus, as well induced lysis of eukaryotic cells (73). Interestingly, the longer synthetic peptide
was more effective against human erythrocytes and the shorter variant more active against bacterial
isolates. While this is the first type I toxin shown to be able to induce toxicity when applied
externally to cells, more analysis will be needed to confirm that sufficient SprG1 is produced and
released from cells to cause killing under native, endogenous conditions.
Nucleic acid cleavage Almost all type I toxins described to date have a putative transmembrane
domain that is thought to contribute to membrane damage upon their production. However, both
SymE and RalR do not follow this paradigm. Overproduction of both SymE (SymE/SymR) and
RalR (RalR/RalA) toxins were toxic to E. coli, yet co-expression of their cognate antitoxin (SymR
or RalA) could prevent this toxicity (25,27). SymE, is a rather “large” protein for a type I toxin at
113 amino acids in length. SymE acts as a ribonuclease and its overproduction triggers mRNA
degradation [for a more thorough discussion of the unusual homology of SymE see (25,74)].
Interestingly, SymE, like TisB and DinQ, is also induced by DNA damage and under the control
of the LexA promoter. Thus, three type I toxins of E. coli are triggered by the SOS response,
signifying the importance of DNA stability and repair for cell survival.
The RalR toxin is encoded on the rac prophage in the genome of E. coli along with its
cognate antitoxin-encoding gene ralA (27). RalR was shown to cleave DNA in an in vitro assay,
but not RNA, suggesting it functions as a DNase. Deletion of either ralR alone or ralR/ralA locus
in E. coli resulted in greater sensitivity towards fosfomycin, an antibiotic that inhibits peptidoglycan
biosynthesis (27). It will be interesting to see how the DNase activity of RalR could lead to
increased resistance to a cell wall synthesis inhibitor.

IV. Perspectives
Despite our growing understandings of the bacteria type I TA systems, many questions remain to
be answered. For example, the detailed mechanisms underlying the versatile roles of the type I
toxins are largely unclear. Additionally, it is not known whether an antitoxin sRNA can regulate
other target(s) besides the cognate toxin gene. This is particularly interesting given the
observations that many trans-encoded sRNAs use different regions of the sequences to regulate
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expression of multiple genes [reviewed in (75)]. Moreover, the evolution of the type I loci as well
as potential functional connections between type I and other types of TA systems are fascinating
areas to be examined.

V. Research objectives
A previous bioinformatics search had identified two highly homologous gene pairs in E. coli
O157:H7 (EHEC) likely belonging to a type I TA system (40). We renamed these two loci as zorOorzO and zorP-orzP. The zorO and zorP genes encode for small proteins of 29 amino acids, while
the orzO and orzP genes encode for sRNAs of ~80 nts. Since these are newly identified gene pairs,
it is unclear if they are true type I TA loci and how the putative toxin genes are regulated. The
overarching goal of this dissertation was to characterize the gene pair zorO-orzO and to understand
the regulation of zorO gene in EHEC.
When beginning this project, I noted that the OrzO sRNA shares extensive sequence
complementarity to the zorO mRNA, indicating that these two RNAs can base pair. Base pairing
of the mRNA by the sRNA is a key feature of a type I TA locus. Therefore, I first confirmed that
the zorO-orzO gene pair is a bona fide type I system. Since there are 18 nts of perfect base pairing
potential between the OrzO sRNA and the zorO mRNA, I wanted to know if all 18 nts of base
pairing are needed for OrzO to repress zorO. Using mutational studies, I demonstrated that
successful recognition of the zorO mRNA by the OrzO sRNA requires a minimal of 15 nts of
perfect base pairing potential. Further, I showed that base pairing by the OrzO sRNA can stimulate
degradation of the zorO mRNA in a RNase III-dependent fashion, leading to reduced ZorO
production. Hence, the zorO gene can be regulated at the post-transcriptional level by the OrzO
sRNA. These results are presented in chapter 2.
Along with this, I wanted to know if repression of zorO by OrzO solely relies on mRNA
degradation. A close examination of the zorO mRNA indicated that it possesses a long 5’ UTR of
174 nts where the OrzO sRNA base pairs. Specifically, the base pairing occurs at a region located
~60 nts upstream of the zorO RBS in this long 5’ UTR. Given this, I asked why the zorO 5’ UTR
was so long and whether base pairing by OrzO could impact zorO translation despite the fact that
the base pairing site is far from the translation initiation region of zorO. To address these questions,
I determined the roles of zorO 5’ UTR using a combination of in vivo and in vitro assays. I showed
that the 5’ UTR could modulate zorO translation through two independent regions, both of which
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are required for zorO to achieve optimal translational efficiency. Interestingly, one of the region
overlaps the base pairing site of zorO. Hence, binding by the OrzO sRNA at this site interferes
with zorO translation. These findings expanded the work shown in chapter 2 and indicated that the
zorO gene can also be regulated at the translational level by both its own 5’ UTR and the OrzO
sRNA. These results are presented in chapter 3.
Given my findings that the zorO gene is regulated at multiple levels, I was curious as to
why so many layers of regulation are needed to control ZorO production. Although zorO
overexpression causes bacterial growth stasis or cell death, the mechanism underlying the toxic
nature of ZorO remained elusive. Predictive tools have suggested that ZorO can target the
cytoplasmic membrane; however, this had never been experimentally tested. Indeed, I found that
overproduction of ZorO leads to rapid membrane depolarization, confirming that it functions at
the cell membrane. Interestingly, despite its hydrophobicity, the ZorO protein contains several
charged amino acids and two of them are predicted in the putative transmembrane domain of ZorO.
I thus focused on the roles of these two charged amino acids and demonstrated that they are critical
for ZorO’s toxicity. These findings provided much-needed information on the biochemical
properties of the ZorO toxin and shed light on elucidating its biological function. These results are
presented in chapter 4.
Taken together, the work presented in this dissertation expands the current knowledge of bacterial
type I toxin-antitoxin systems and provides new insights into the regulatory mechanisms
controlling the production of the type I toxin ZorO in EHEC.
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Appendix I: chapter I tables and figures
Table 1.1. Features of described type I toxin-antitoxin loci

Locus

Founding member
(Plasmid or
bacterium)a

hok/sok

Plasmid R1 (16)

Inhibit protein synthesis
Stimulate mRNA degradation

fst/RNAII

Plasmid pAD1 (21)

Inhibit protein synthesis

bsrG/sr4

Bacillus subtilis (30)

Inhibit protein synthesis
Stimulate mRNA degradation

symE/symR

Escherichia coli (25)

Inhibit protein synthesis
Stimulate mRNA degradation

ibs/sib

Escherichia coli (64)

Inhibit protein synthesis
Stimulate mRNA degradation

ralR/ralA

Escherichia coli (27)

Inhibit protein synthesis

tisB/istR-1

Escherichia coli (28)

Inhibit protein synthesis
Stimulate mRNA degradation

Genetic organizationb

Mode of antitoxin action
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Table 1.1. (continued)

a

Locus

Founding member
(Plasmid or
bacterium) a

txpA/ratA

Bacillus subtilis (21)

Stimulate mRNA degradation

bsrE/sr5

Bacillus subtilis (33)

Stimulate mRNA degradation

bsrH/as-bsrH

Bacillus subtilis (66)

Stimulate mRNA degradation

Genetic organizationb

Mode of antitoxin action

The founding member (first description) of each toxin-antitoxin locus is indicated. Note that

many homologs to these systems have been identified and characterized; the text gives details of
those; b The toxin mRNA is represented by the blue arrow with the coding region shown as the
blue box. The antitoxin RNA is represented by the red arrow.
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Figure 1.1. Repression of the BsrG toxin production by the SR4 antitoxin. The ribosome
binding site (yellow) of the bsrG mRNA is normally located in a 4-nt-long stem. Binding by the
SR4 antitoxin sRNA (red) causes structural changes of this stem and results in extension of the
stem to 8-nt-long, which leads to reduced translation of the bsrG mRNA. This interaction with the
antitoxin sRNA can also trigger toxin mRNA degradation.
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Figure 1.2. Repression of the IbsC toxin production by the SibC antitoxin. The ibs mRNA
(blue) is translated by the ribosome (purple) when the Sib antitoxin (red) is not present. Binding
of the SibC antitoxin RNA (red) blocks translation as it overlaps the ribosome binding site (yellow)
and the translation initiation codon and then can potentially extend over the entire coding region.
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Figure 1.3. Repression of the Hok toxin production by the Sok antitoxin. The hok mRNA (blue)
must first be processed at its 3' end prior to interaction with either the ribosome (purple) or the Sok
sRNA (red). Translation of the hok mRNA is dependent upon translation of an upstream open
reading frame mok (grey) by the ribosome. Binding of the Sok antitoxin RNA (red) blocks
translation of the leader peptide, thus preventing toxin expression.

29

Figure 1.4. Repression of the TisB toxin production by the IstR-1 antitoxin. Translation of
the tisB mRNA is dependent on both a processing event and binding of the ribosome (purple) to a
standby site (pink) as the real toxin ribosome binding site (yellow) is sequestered in a secondary
structure. First, the full-length tisB mRNA (blue) must be processed at its 5' end in order for the
IstR-1 sRNA (red) or the ribosome to bind. Following processing, the standby site (pink) is
accessible to the ribosome (purple) and the antitoxin (red). Binding by the IstR-1 antitoxin will
block binding of the ribosome to the standby site. In the absence of the antitoxin, the ribosome can
bind to the standby site and then onto the true ribosome binding site (yellow).
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Figure 1.5. Repression of the TxpA toxin production by the RatA antitoxin. The txpA toxin
mRNA (blue) can be translated by the ribosome (purple) to produce the toxic protein. However, if
the antitoxin RatA (red) is present and interacts with the toxin, RNase III can cleave the doublestranded complex, thereby initiating mRNA degradation which eventually prevents toxin
translation.
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CHAPTER II

The ZorO-OrzO type I toxin-antitoxin locus:
repression by the OrzO antitoxin
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Publication note
A version of this chapter was originally published by Jia Wen, Daniel Won, and Elizabeth M. Fozo:
Jia Wen, Daniel Won, and Elizabeth M. Fozo. “The ZorO-OrzO type I toxin-antitoxin locus:
repression by the OrzO antitoxin.” Nucleic Acids Research (2014) 42 (3):1930-1946.
My contribution to this paper was mutant constructions, rescue experiments, RNA isolation,
northern analyses, quantification of RNA levels, and most of the literature review and writing.
Daniel Won assisted generating data presented in Figure 2.3, where he performed the rescue
experiment with wild type Escherichia coli O157: H7 and ∆rnc mutant as well as the
corresponding northern analyses. Dr. Elizabeth Fozo performed the primer extension assay
represented in Figure 2.4B. I performed all other experiments.
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Abstract
Type I toxin-antitoxin loci consist of two genes: a small, hydrophobic, potentially toxic protein,
and a small RNA (sRNA) antitoxin. The sRNA represses toxin gene expression by base pairing to
the toxin mRNA. A previous bioinformatics search predicted a duplicated type I locus within
Escherichia coli O157:H7 (EHEC), which we have named the gene pairs zorO-orzO and zorPorzP. We show that overproduction of the zorO gene is toxic to E. coli; co-expression of the sRNA
OrzO can neutralize this toxicity, confirming that the zorO-orzO pair is a true type I toxin-antitoxin
locus. However, OrzO is unable to repress zorO in a strain deleted for RNase III, indicating that
cleavage of the target mRNA is critical for repression. Sequence analysis and mutagenesis studies
have elucidated a nucleotide sequence region (V1) that allows differential recognition of the zorO
mRNA by OrzO and not OrzP, and a specific, single nucleotide within the V1 of OrzO that is
critical for repression of zorO. Although there are 18 nucleotides of complementarity between the
OrzO sRNA and the zorO mRNA, not all base pairing interactions are needed for repression;
however, the amount needed is dependent upon whether there is continuous or discontinuous
complementarity to the target mRNA.
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I. Introduction
As a newly recognized class of gene expression regulators, small, non-coding RNAs have been
found in all kingdoms of life. In bacteria, these RNAs are referred to as sRNAs (small RNAs) and
are often 50-300 nt in length. Some sRNAs bind to proteins and modulate their functions, as
exemplified by the CsrB RNA of Escherichia coli, which directly binds and sequesters the CsrA
protein, thus affecting carbon metabolism in E. coli (1). However, the majority of characterized
sRNAs function by base pairing to target mRNAs, either regulating the translation or altering the
stabilities of the targets.
These base pairing sRNAs fall into two categories: trans-encoded sRNAs and antisense
sRNAs. Trans-encoded sRNAs are located at chromosomal positions distal from the genes they
regulate. These sRNAs typically interact with their targets by limited base pairing and often require
the RNA chaperone Hfq to function [reviewed in (2)]. True antisense sRNAs are encoded on the
opposite strand of DNA to their targets. They share extensive base pairing potential (usually 60 nt
or more) to their target mRNAs [reviewed in (3,4)]. Although antisense sRNAs were initially
discovered on mobile genetic elements, several pairs have been described on bacterial
chromosomes [reviewed in (5)].
A subset of antisense sRNAs in bacteria can repress the expression of small proteins under
60 amino acids in length. These proteins are usually very hydrophobic and toxic when
overproduced. The sRNA (antitoxin) base pairs with the toxin mRNA and affects the translation
and/or the stability of the mRNA. Gene pairs consisting of a toxic protein-encoding gene and a
corresponding antitoxin sRNA-encoding gene are referred to as type I toxin-antitoxin systems. The
first type I pair to be identified was the hok/sok locus of the R1 plasmid in E. coli, whereby Hok
is the toxin, and Sok the antitoxin (6). The hok mRNA has a very long half-life while the Sok
sRNA has a short half-life. When cell division occurs, a daughter cell that has not inherited the R1
plasmid will die due to the quick degradation of the Sok sRNA and the translation of the more
stable hok mRNA. Besides the hok/sok locus, several type I toxin-antitoxin gene pairs have been
described on other plasmids in gram negative bacteria and were also shown to play a role in
plasmid maintenance [reviewed in (7)]. Additionally, the RNAI-RNAII locus of the pAD1 plasmid
of Enterococcus faecalis clearly showed that similar loci were present in gram positive bacteria
(8-10). Homologs of these plasmid loci were later found within bacterial chromosomes (11-14).
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In recent years, several type I toxin-antitoxin systems that do not have homology to plasmid
sequences have been identified and characterized in a number of bacterial chromosomes. Although
both the toxin and antitoxin-encoding genes are located at the same locus, their relative positioning
varies among the chromosomally encoded type I pairs. Some antitoxins overlap with the 5’
untranslated region (UTR) of their targets, such as the Rdl sRNAs of the Ldr-Rdl family in E. coli
(15), or the 3’ UTR, like RatA and SR4 of the TxpA-RatA and BsrG/SR4 loci of Bacillus subtilis
(16,17). Others directly overlap with the coding sequences of the target mRNAs, as exemplified
by the Ibs-Sib family of E. coli in which Sib sRNA completely overlaps with the ibs mRNA coding
region (18).
Along with these, there are a few unconventional type I loci in which the antitoxins are
encoded divergent from the toxin-encoding genes [reviewed in (19)]. Unlike the traditional type I
loci that can have 60 nt or more base paring potential, the unconventional type I loci have limited
base pairing, often only 18-21 nt. These loci include the TisAB-IstR and the ShoB-OhsC pairs in
E. coli (18,20).
A previous bioinformatics search identified two highly homologous loci encoded in tandem
in the chromosome of E. coli O157:H7 EDL933 (EHEC) (14). Each locus includes two genes: one
encodes a small hydrophobic protein, and the other encodes an sRNA that is located divergently
from the protein-encoding gene. This genetic organization is very similar to that of the type I toxinantitoxin pairs ShoB-OhsC and TisAB-IstR. In the two newly identified loci, the small proteinencoding genes (29 amino acids) were previously annotated as z3289 and z3290. We have since
renamed z3289 and z3290 as zorO (Z protein often repeated) and zorP respectively. Additionally,
we have denoted the sRNA gene divergent from zorO as orzO (overexpression represses zor
toxicity) and the sRNA gene divergent from zorP as orzP (Figure 2.1A; all tables and figures are
located in the appendix). The sRNAs contain regions of complementarity (18-19 nt) to the mRNAs,
suggesting that they could base pair. In addition, the zor-orz loci are highly conserved in most
commensal and pathogenic E. coli and Shigella strains but not in the common lab strains, like E.
coli MG1655 (14).
Overexpression of ZorO was shown to be toxic; however, it was never demonstrated that
the sRNA OrzO could repress zorO-induced toxicity (14). Thus, is zorO-orzO a true type I toxinantitoxin locus? Given the high homology between the zorO-orzO and zorP-orzP loci, is there
“cross-talk” in the regulation? In this study, we confirmed that the zorO-orzO locus is indeed a
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true type I toxin-antitoxin system. Utilizing the inherent toxicity associated with zorO
overproduction, we performed mutational analyses to further investigate the requirements for
successful repression by the OrzO antitoxin. Through these analyses, we revealed that the 5’ end
of the OrzO sRNA can solely repress zorO and the V1 region within 5’ end of the Orz sRNA
determines the specific recognition of the zor target.

II. Materials and Methods
Bacteria strains and plasmids All bacterial strains and plasmids utilized in this work are listed
in Table 2.1. The sequences of all oligonucleotides are listed in Table 2.2.
Growth conditions E. coli strains were grown at 37°C in LB medium with shaking. Antibiotics
were added when necessary at the following concentration: 100 µg/mL ampicillin, 25 µg/mL
chloramphenicol, 25 µg/mL kanamycin. Arabinose was added to a final concentration of 0.2 or
0.002% as indicated. IPTG, when used, was at a final concentration of either 0.1 mM or 1 mM, as
indicated.
Generation of strains for rescue experiments All strains used in the described rescue
experiments are derived from DJ624 which contains ΔlacX74 and does not possess the zor-orz
locus (21). To better control expression from the PBAD promoter across the population of cells, the
araE gene was placed under control of the PCP18 constitutive promoter through P1 transduction of
the kan-PCP18-araE allele (22). The kanamycin cassette was then removed using pCP20, resulting
in strain UTK007 (23). Generation of the hfq and rnc deletions was performed using the mini-λRed recombination system (24-26). In each case, pKD4 served as a PCR template for amplifying
the kanamycin cassette using primers containing 20 nt of homology to the kanamycin cassette,
flanked by approximately 40 nt of homology to the chromosomal region (25).
Plasmid construction For overexpression of the sRNAs OrzO and OrzP, the genes were amplified
from genomic DNA (E. coli O157:H7 EDL933) and ligated into the AatII and EcoRI sites of pBRplac generating pBR-plac-orzO and pBR-plac-orzP (21). The zorO gene was ligated into the PstI
and HindIII sites of pEF21 from the mapped +1 of its transcription, generating pEF21-zorO
(pBAD-zorO in the text) (14,18). Mutations of individual nucleotide residues for all constructs
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were performed by site-directed mutagenesis of either pBR-plac-orzO, or pBR-plac-orzP, or
pEF21-zorO. For generation of pBR-pLac-orzO 6(1)10(1) and pBR-plac-orzO (1)5(1)11, pBRplac-orzO 6(1) 11 served as the template. The two chimeric constructs, pBR-plac-orzO-ohsC and
pBR-plac-orzO-istR, were generated using SOE PCR (27,28). PCR product A amplified the first
18 nucleotides of orzO from pBR-plac-orzO along with 100 nt upstream of vector sequence
(including the AatII cut site); the 3’ end of the product contained 15 nt of PCR product B. PCR
product B amplified either ohsC or istR from E. coli O157:H7 EDL933 genomic DNA; this product
began immediately following the region of base pairing that these RNAs would have for their
respective targets (18,20). The 5’ end of PCR B contained 15 nt of homology to the 5’ end of orzO.
The products were then spliced together via PCR, digested with AatII and EcoRI, and ligated into
pBR-plac. Plasmid DNA was isolated using the Qiagen Mini Plasmid Kit; PCR products were
isolated using the Qiagen PCR Purification Kit.
Rescue experiments Rescue experiments were as described previously (15,18). The pBR-plac
plasmid carrying the orz wild type/ mutant gene under an IPTG-induced PLlacO-1 promoter was
initially transformed into UTK007 or one of the derivatives described above, through
electroporation (21). Afterwards, the pEF21 plasmid containing the zor wild type/mutant gene
under an arabinose-induced PBAD promoter was transformed into the same cells (29). The resulting
transformants harboring two plasmids were grown overnight and then diluted to OD600 of 0.01.
When the OD600 reached ≈ 0.1, the cultures were split and IPTG was added to half the culture to a
final concentration of either 0.1 mM or 1 mM for the overexpression of the orz gene. Thirty
minutes after IPTG induction, arabinose was added to a final concentration of either 0.002% or
0.2% for the overproduction of the zor gene. OD600 was taken and recorded every 30 minutes.
Shown are averages ± standard deviations for a minimum of three independent experiments.
RNA extraction In order to examine RNA levels of zorO and OrzO, cells harboring the
appropriate plasmids were grown to an OD600 ≈ 0.2, and arabinose was added as indicated to induce
zorO (time 0). Five minutes post-induction with arabinose, the culture was split and IPTG (0.1
mM or 1 mM) was added to half. RNA was extracted via direct lysis as previously described with
some modifications (30). Cells (750 µL aliquots) from time 0, 5, 15, 30, and 60 minutes postarabinose were harvested and incubated at 65°C with 500µL acid phenol: chloroform (preheated
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to 65°C) and 102 µL of direct lysis solution (320 mM sodium acetate, 8% SDS, 16 mM EDTA)
for 10 minutes. After incubation, the mixtures were centrifuged at 13000 rpm at room temperature
for 10 minutes. Supernatants were transferred to tubes containing 500 µL of 65°C phenol:
chloroform, mixed thoroughly and spun again for 10 minutes at room temperature. The
supernatants were transferred and extracted twice with 400 µL phenol: chloroform. The RNA was
then ethanol precipitated and resuspended in RNase free water. When needed, RNA was treated
with Turbo DNaseI (Life Technologies) following manufacturer’s instructions.
Northern analysis Total RNA (10 µg) isolated at indicated time points following arabinose
induction was separated on a denatured 6% (for the separation of zor mRNA) or 8% (for the
separation of orz sRNA) polyacrylamide-urea gel and transferred to a Zeta-Probe Genomic GT
membrane (Bio-Rad). Specific probes were generated by end-labeling oligonucleotides with ɣ-32P
by T4 polynucleotide kinase. Incubation of the membrane and washes were performed as outlined
by Opdyke et al (31). Northern analysis was performed from a minimum of three independent
experiments for every construct examined.
Quantification of RNA levels The relative intensities of the resulting bands from northern
analysis detected via autoradiography were quantified using ImageJ (32). The intensity of the band
for WT at T15 (induced with the level of IPTG indicated) was set to a value of “1” as a standard
for comparison. Relative intensities to WT at T15 for the other bands on the same northern blot
were thus calculated. Averages and standard deviations were determined, and the statistical
significance was calculated using Student’s t test.
Primer extension Total RNA (5 µg) isolated thirty minutes post arabinose induction from rescue
experiments was separated on a denatured 8% polyacrylamide-urea gel as described previously
(18,31).

III. Results
zorO-orzO is a bona fide type I toxin-antitoxin locus The zorO gene of E. coli O157:H7 EDL933,
initially annotated as z3289, was predicted to be type I toxin (14). Overexpression of the small
protein from a high-copy plasmid in E. coli MG1655 led to cell growth stasis as well as a decrease
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in colony forming units, indicating that ZorO is toxic (14). In the same study, the sRNA OrzO
(denoted at that time as sRNA-1) was detected via northern analysis. This sRNA, though encoded
divergent from the toxin gene, could potentially base pair with the 5’ UTR of the zorO mRNA
(Figure 2.1A, 2.1B).
Despite these data, the crucial question remained whether the zorO-orzO pair is a true type
I toxin-antitoxin locus. If so, then the OrzO sRNA should be able to repress the toxicity of ZorO
overproduction. Rescue experiments were employed to test if OrzO can repress ZorO. We
expressed zorO from an arabinose-inducible promoter (PBAD) on one plasmid and orzO from an
IPTG-inducible promoter (PLlacO-1) on a second compatible plasmid (15,18). These experiments
were performed in a strain derived from E. coli MG1655 that does not possess the zor-orz loci so
as to eliminate any possible repression from a chromosomally encoded OrzO. While the induction
of zorO led to cell growth stasis, indicating that ZorO is toxic, the co-expression of OrzO prevented
this cell stasis, suggesting that OrzO serves as an antitoxin for ZorO (Figure 2.1B). Thus, we
conclude that the zorO-orzO pair is a true type I toxin-antitoxin locus.
RNase III but not Hfq is critical for repression of zorO-induced toxicity The majority of transencoded sRNAs characterized to date require the RNA chaperone Hfq to function efficiently
whereas the antisense sRNAs typically do not (2,7,33). However, given that there is limited
complementarity between the zorO mRNA and the corresponding OrzO sRNA (18 nt perfect
complementarity), we wanted to examine whether Hfq is required for the observed repression of
the ZorO toxin. A similar rescue experiment was performed as outlined above in a strain deleted
for hfq. The results showed that the OrzO sRNA can fully repress zorO in both the wild type and
the Δhfq strain (Figure 2.2), indicating that Hfq is not needed for the OrzO sRNA to regulate zorO.
RNase III, a double-stranded ribonuclease, has been shown to be critical for cleaving paired
toxin-antitoxin complexes including hok/sok, tisB-istR, bsrG/sr4, txpA-ratA, as well as for the
sRNA GadY and its mRNA target gadX-gadW (16,20,34,35,38). To determine whether repression
by OrzO was dependent upon expression of RNase III, we performed our rescue experiment in a
strain deleted for rnc, the gene encoding RNase III. The results (Figure 2.3A) show that OrzO is
incapable of rescuing zorO-induced toxicity in this mutant, even at low levels of inducing agent
(0.002% arabinose, see below; data not shown). When zorO is expressed with OrzO in a wild type
strain, we detect major transcripts of approximately 280 and 310 nt in length via northern analysis
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(Figure 2.3B). When examining zorO in the Δrnc strain, we noted an accumulation of these fulllength transcripts in comparison to expression in the wild type strain, suggesting that the fulllength mRNAs are more stable in the deletion strain (Figure 2.3B). This implies that cleavage of
the zorO-OrzO RNA duplex by RNase III is important for repression of zorO-induced toxicity.
Surprisingly, OrzO levels (induced by 1 mM IPTG) appear reduced in the Δrnc strain (Figure
2.4A).
We attempted to map the cleavage sites of zorO when OrzO is expressed in a wild type and
a Δrnc strain using primer extension. Similar to our northern analyses, we noted an accumulation
of full-length zorO mRNA in the Δrnc strain even when OrzO is expressed (Figure 2.4B). However,
we are able to map OrzO-specific cleavage sites within the zorO mRNA in the Δrnc strain (Figure
2.1A, 2.4B), similar to what has been reported for cleavage of gadX-gadW by GadY and cleavage
of cII-O by the OPP RNA (35-37). This finding suggests that while RNase III may be critical for
regulation of zorO repression, there may be additional factors involved (see Discussion). As
summarized in Figure 1A and shown in Figure 2.4B, the major processing sites lie within the
region of base pairing for both the wild type and Δrnc strain. We did note that in the Δrnc strain
there were sites that appear to be shifted from the wild type cleavage sites, as well as decreased
cleavage at some sites (Figure 2.1A, 2.4B). We also detected processing outside the region of base
pairing for both strains (Figure 2.1A, 2.4B), but it is not clear at this point the origin of these
products.
5’ end of the OrzO sRNA can solely repress zorO A previous study has shown that the antitoxin
IstR-1 of E. coli regulates its toxin target TisB by 5’ end pairing (20). Similarly, the OhsC antitoxin
is predicted to base pair to its target ShoB through its 5’ end (18). In zorO-orzO pair, the longest
stretch of potential base pairing between OrzO and the zorO mRNA also occurs in the immediate
5’ end of OrzO. To test if just the 5’ end of OrzO can repress zorO, we first constructed two OrzO
mutants truncated at the 3’ end. However, we were unable to detect the expression of these
truncated sRNAs (data not shown). We hypothesized that the inability to detect these truncated
RNAs was due to their instability; therefore, we generated chimeric sRNAs to the OhsC and IstR1 sRNAs. The base pairing regions that OhsC and IstR-1 had to their own toxins were replaced
with the first 18 nt of the 5’ end of the OrzO sRNA (Figure 2.5A). Consequently, only the 5’ end
of the chimeras can base pair with the zorO mRNA. Rescue experiment results showed that
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although the wild type OhsC and IstR sRNAs failed to repress zorO, both chimeras successfully
repressed the expression of zorO (Figure 2.5B, 2.5C). This demonstrates that the first 18 nt of
OrzO are sufficient for full repression.
Orz regulation is target specific The 5’ end of OrzO contains a continuous stretch of 18 nt that
can base pair to the zorO mRNA (Figure 2.1B). The OrzP sRNA, which is a homolog of OrzO,
also shares a total of 15 nt complementarity to zorO (Figure 2.6B). Because of the sequence
similarities between OrzO and OrzP, it is possible that OrzP is capable of regulating ZorO (Figure
2.6A).
Rescue experiments were used to determine whether the OrzP sRNA can repress the
expression of zorO. When OrzO was co-expressed with zorO, the strain was able to grow. However,
when OrzP was co-expressed with zorO, cell stasis occurred (Figure 2.6C), suggesting that only
OrzO, but not OrzP, can repress zorO. We also confirmed that OrzP was being expressed at levels
equivalent to or higher than OrzO by northern analysis (Figure 2.7), which indicates that the failure
of OrzP to rescue is not due to expression differences. Thus, repression by the Orz sRNAs is targetspecific.
V1 region determines OrzO specificity for zorO Although OrzO and OrzP share the same
predicted base pairing region with zorO, only OrzO is able to repress zorO. To further investigate
what dictates this specificity, we compared the sequences of the two sRNAs (Figure 2.6A). Despite
the great sequence similarity between OrzO and OrzP, there are several differences. In particular,
the nucleotide sequences from +9 to +11 compose a variable region of 3 nt between OrzO (GAA)
and OrzP (ACG). Indeed, this variable region (referred to as V1) is the most prominent difference
observed within the 5’ regulatory domain of the two sRNAs.
To determine if this V1 region is responsible for specificity in the OrzO regulation of zorO,
the three nucleotides in the V1 region of OrzO were changed from “GAA” to “ACG”, the sequence
found in OrzP (Table 2.3). We then tested the ability of the resulting mutant strain (15 nt of base
pairing potential) to rescue cells from zorO-induced toxicity. Our results showed that the OrzO V1
mutant completely failed to rescue cells (Figure 2.6D), suggesting that the V1 region is critical for
repression by the OrzO sRNA.
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To confirm these results, we generated compensatory mutations in zorO (referred to as
zorO V1) so as to restore complementarity to the OrzO V1 mutant. Indeed, restoring the base
pairing allowed the OrzO V1 to fully repress ZorO V1 induced toxicity (Figure 2.8). These data
implied that the V1 region is important for OrzO to recognize its target.
Furthermore, we engineered an OrzP V1 mutant, in which its V1 region was changed from
“ACG” to “GAA”, the sequence found in OrzO. Consequently, the OrzP V1 mutant has increased
ability to base pair to zorO, as it could perfectly match zorO in the V1 region (Table 2.3). Unlike
the OrzP WT, which cannot inhibit zorO mRNA expression, the OrzP V1 mutant fully represses
zorO (Figure 2.6D). These data, in addition to the observations from the zorO WT-OrzO V1 pair
and the zorO V1-OrzO V1 pair, further support the hypothesis that the V1 region is responsible
for the Orz sRNA specificity to its zor target.
The first base of the V1 region is critical for OrzO regulation of zorO Since the V1 region of
the 5’ end of OrzO is composed of three nucleotides (GAA), we then asked whether all three
nucleotides contribute equally to the ability of OrzO to regulate zorO. Each nucleotide of the V1
region was mutated individually and tested for the ability to rescue cells from zorO-toxicity. The
resulting mutants are named OrzO 8(1)9, OrzO 9(1)8 and OrzO 10(1)7. These are named such that
the number in the parentheses indicates the number of unpaired nucleotides, while the numbers on
the two sides of the parentheses represent the number of the nucleotides within the 5’ end of OrzO
that are capable of base pairing with zorO (Table 2.3). For example, in OrzO 8(1)9, the first 8 nt
of OrzO can pair to zorO, followed by a single unpaired nt, and then 9 nt of pairing.
Rescue experiments were used to assess the repression abilities of the three mutants.
Interestingly, the repression ability of the single mutants was not equivalent. The point mutation
in the first nucleotide of the V1 region of OrzO completely abolished the repression ability of
OrzO sRNA (Figure 2.9A), as the OrzO 8(1)9 mutant failed to rescue cells even at a low induction
level of zorO (0.002% arabinose, see below). Northern analysis further indicated that the OrzO
8(1)9 mutant showed levels equivalent to that of the OrzO wild type (WT) at T15 and T60,
suggesting that the failure of the OrzO 8(1)9 mutant to rescue is due to mutating the first nucleotide
of the V1 region (Figure 2.9B, 2.10A). Mutation of the third nucleotide of the V1 region did not
affect the repression ability of OrzO, as the OrzO 10(1)7 mutant still fully repressed zorO (Figure
2.9C).
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The OrzO 9(1)8 mutant (second nucleotide of the V1 mutated) was highly variable in its
ability to repress zorO (Figure 2.11A), despite generation of the mutant independently multiple
times. To clarify whether this may be due to expression problems, we performed a more in-depth
expression comparison to wild type OrzO. We first examined the basal level of OrzO induction
required to repress zorO, and determined that this occurs at 0.1 mM IPTG induction (Figure 2.12A,
2.12B, 2.13C). We then compared expression of OrzO 9(1)8 when induced at 1 mM IPTG to wild
type OrzO expressed at 0.1mM IPTG (Figure 2.11B, 2.11C). Indeed, expression of OrzO 9(1)8 is
higher than the basal levels of wild type OrzO that is needed for zorO repression. This suggests
that the attenuated repression ability observed in OrzO 9(1)8 is likely due to the nucleotide change
rather than the expression difference. Regardless, our results imply that the first nucleotide of the
V1 region is most critical for the OrzO sRNA to regulate zorO.
15 nt of continuous base pairing interactions are sufficient for OrzO regulation We have
shown that the 5’ base pairing domain of OrzO is critical for regulating zorO and the V1 region
dictates the correct recognition of the cognate zor targets. However, it is not clear whether all
nucleotides within the 5’ end of OrzO besides the V1 region are needed for repression of zorO. To
better refine the requirements for successful base pairing, we generated two deletion constructs in
which the first 3 and 6 nt were deleted from the 5’ end of OrzO while leaving the V1 intact. The
OrzO Δ3 and Δ6 share a continuous stretch of 15 nt and 12 nt complementarity with zorO mRNA,
respectively (Table 2.3).
Rescue experiments were used to assess the abilities of these two mutants to repress zorO.
Neither the OrzO Δ3 nor Δ6 completely repressed zorO when we used 0.2% arabinose to induce
expression of the toxin (Figure 2.13A, data not shown). We also inspected the levels of OrzO Δ3
and Δ6 and observed that their levels were decreased as compared to the level of full-length OrzO
when all were induced with 1mM IPTG (data not shown).
Upon closer examination of the rescue experiment using OrzO Δ3, we noticed a “transient”
rescue or a delay in growth stasis compared to expression of zorO alone when induced with 0.2%
arabinose. When we reduced the arabinose concentration to 0.002%, we noted that overproduction
of ZorO still caused cell growth stasis, in a pattern identical to the 0.2% arabinose induction group
(Figure 2.12D, 2.12E). In addition, co-expression of OrzO Δ3 relieved the toxicity caused by
induction of zorO at 0.002%, suggesting that the failure of this mutant to rescue at higher
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concentration of arabinose was likely due to the reduced levels of this sRNA mutant (Figure 2.13A).
However, OrzO Δ6 still could not repress toxicity when ZorO was induced by 0.002% arabinose
(Figure 2.13C).
We observed that the RNA levels of OrzO Δ3 and Δ6 (induced by 1 mM IPTG) were higher
than the basal levels of wild type OrzO (induced by 0.1 mM IPTG) at T15 (Figures 2.13B, 2.13D,
2.10B, 2.10C). The levels of the wild type sRNA continued to increase over time (T30 and T60),
whereas the levels of the truncated sRNAs remained relatively steady. Even though OrzO Δ3 did
not accumulate to a level as high as the wild type sRNA, it was capable of repressing zorO. OrzO
Δ6, however, could not even transiently rescue cells, despite being induced initially to levels higher
than wild type OrzO (Figure 2.13D, 2.10C). Combined, these data imply that 15 nt, but not 12 nt,
of continuous base pairing is sufficient for the OrzO sRNA to repress zorO.
A minimum of 17 nt of discontinuous base pairing interactions is required for OrzO
repression of zorO As shown above, 15 nt of continuous complementarity to zorO is sufficient
for repression. Our OrzP V1 mutant can also repress zorO, but it does not have 15 nt of continuous
base pairing (Table 2.3). Instead, this mutant has 17 nt of discontinuous pairing. This suggests that
the amount of complementary base pairs required for discontinuous base pairing interactions may
be different from that for continuous base pairing interactions.
Given that the OrzP V1 (pairing: 5(1)12) can rescue cells from zorO-induced toxicity, we
designed series of mutants with decreased base pairing potential as compared to OrzP V1 (Table
2.3). We constructed OrzO 5(2)11 with a total of 16 nt of base pairing, which is composed of a 5
nt stretch of complementarity, followed by a 2 nt gap and then another 11 nt stretch of
complementarity. The OrzO 5(2)11 mutant could not repress ZorO toxicity when the mRNA was
induced with either 0.2% or 0.002% arabinose (Figure 2.14A and data not shown). We also
confirmed that the OrzO 5(2)11 mutant (induced by 1 mM IPTG) was being expressed at levels
higher than the basal levels of OrzO WT (induced by 0.1 mM IPTG) at T15 and T30 (Figure 2.14B,
2.10D), suggesting that the failure of OrzO 5(2)11 to rescue is likely not due to insufficient RNA
levels, but rather base pairing differences.
Our OrzO 5(2)11 possesses a total of 16 nt of pairing to zorO, whereas our OrzP V1
possesses 17 nt of pairing (5(1)12). It maybe that a minimum of 17 nt of discontinuous base pairing
is required for repression. To explore this further, we generated several more constructs. The OrzO
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6(1)11 mutant has a total of 17 nt of pairing, and indeed it can fully repress zorO (Figure 2.14C).
We then mutated the last nucleotide of pairing of this construct, generating the OrzO 6(1)10(1)
mutant, which possess a total of 16 nt of pairing. We also generated the OrzO (1)5(1)11 mutant,
in which the first nucleotide of pairing was mutated, and in total, possesses only 16 nt of pairing.
When either mutant was used in a rescue experiment, they were unable to repress toxicity, even if
zorO was induced with 0.002% arabinose (Figure 2.14D). Furthermore, northern analysis indicated
that these mutants (induced by 1 mM IPTG) were expressed at levels equivalent to or even higher
than OrzO WT induced by 0.1 mM IPTG (Figure 2.14E, 2.14F, 2.10E, 2.10F). Thus, the failure to
rescue is likely due to insufficient pairing and not due to insufficient production of the antitoxin.

IV. Discussion
In this study, we show that the zorO-orzO gene pair of E. coli O157:H7 is a true type I toxinantitoxin locus. More specifically, our data are consistent with the properties of an unconventional
type I system, as the OrzO antitoxin is encoded divergently from zorO and has limited base pairing
potential with it. Overproduction of ZorO is toxic, however, co-expression of OrzO represses this
toxicity and rescues the cells. We discovered that the 5’ end of OrzO can solely repress zorOinduced toxicity, and the V1 region dictates the correct recognition of zorO. Furthermore, the first
base of the V1 region is critical for the OrzO sRNA to regulate the expression of zorO mRNA.
Although there is 18 nt complementarity with zorO at the 5’ end of OrzO, not all base pairing
interactions are needed for repression. For continuous complementarity, 15 nt of perfect base
pairing is sufficient to function, while for discontinuous complementarity, a minimum of 17 nt of
perfect base pairing is required to maintain the repression ability if a single non-pairing nucleotide
is present within the base pairing region.
Role of RNase III in repression of zorO expression Ribonuclease III (RNase III), encoded by
the rnc gene, cleaves double-stranded RNA, and has been linked to processing of several type I
toxin-antitoxin pairs found in E. coli and B. subtilis (16,20,34). While RNase III is not essential
for growth in E. coli, deletion of the gene in B. subtilis is lethal. Work by Durand, et al. has shown
that the essentiality of RNase III in B. subtilis is because it cleaves the type I toxins txpA and yonT
(38). Interestingly, while the RNA duplex of another type I toxin-antitoxin locus in B. subtilis,
BsrG/SR4, is cleaved by RNAse III, repression of the toxin does not require this ribonuclease (16).
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Thus, while RNase III plays a role in the processing of several described type I pairs in both E.
coli and B. subtilis, its essentiality for repression can be variable between the different systems.
RNase III is also involved in the processing of other RNA duplexes that are not type I
toxin-antitoxin systems. These include the interaction of the mRNA gadX-gadW with the sRNA
GadY and the interaction of the mRNA cII-O with the OOP RNA of λ (35,37,39). For the zorOorzO pair, deletion of RNase III led to accumulation of the full-length zorO mRNA, and in this
strain background, zorO-induced toxicity could not be repressed by co-expression of OrzO. Yet,
we still could detect OrzO-dependent processing of zorO in a Δrnc strain. Similar observations
were seen with gadX-gadW and cII-O; cleavage still occurred without RNase III, although the
processing sites were slightly shifted (35,37,39). We observed a similar shift in the processing of
zorO in a Δrnc strain (Figure 2.1A, 2.4B). There are other ribonucleases within E. coli that may
be contributing to this processing [reviewed in (40)]. For example, RNaseE is critical for the
function of many Hfq-dependent base pairing RNAs [reviewed in (41)]. Further analysis is needed
to determine what other enzymes may be contributing to processing of zorO-OrzO; however, based
on the in depth analysis of the gadX-gadW processing by GadY, it is possible that an
uncharacterized double-stranded ribonuclease may exist (35).
We were surprised to note that the levels of OrzO were reduced in a Δrnc strain; we have
observed that the chromosomal expression levels of OrzO within an E. coli O157:H7 deleted for
rnc are also decreased in comparison to a wild type strain (Wen and Fozo, unpublished
observations). We had anticipated that the levels of OrzO would either be unaffected by the loss
of RNase III or perhaps higher, as there would be decreased cleavage of the zorO-OrzO RNA
duplex. It maybe that RNase III cleaves OrzO directly, and that this cleavage impacts its stability
and/or activity. However, we have been unable to detect alternative forms of OrzO, and cannot
conclude that this is occurring.
Regulation of ZorO by the 5’ end of OrzO To determine whether the 5’ end of OrzO was
sufficient for regulating zorO, we generated two constructs expressing either the first 42 or 34 nt
of OrzO. These truncated sRNAs did not rescue, nor were we ever able to detect their
overexpression (data not shown). However, our chimeric sRNAs, OrzO-OhsC (75 nt) and OrzOIstR (72 nt) were stable and able to rescue E. coli from ZorO toxicity. Thus, although the 5’ end
of OrzO is sufficient for repression, additional RNA sequence at the 3’ end may be needed for
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stability. Many type I antitoxins are predicted to have extensive secondary structure (7). The reason
for such extensive structure among the type I antitoxins has not been thoroughly examined, but
our data suggests that it may be required to prevent quick degradation of the sRNA.
Our data shows that the OrzO sRNA represses zorO expression through base pairing
interactions between the 5’ end of OrzO and the 5’ UTR of zorO. The binding region in the 5’ end
appears to be conserved across many sRNAs. For example, a previous study that examined 18
well-characterized E. coli/Salmonella Hfq-dependent sRNAs found that more than one third used
their 5’ ends to repress their targets (42). In addition, the Hfq-independent sRNA IstR-1 also acts
by 5’ end pairing [reviewed in (19)]. Similar interactions have been predicted to occur with the
shoB-ohsC pair, in which the 5’ end of OhsC shares 19 nt of complementarity to the 5’ UTR of
shoB [(18) and reviewed in (19)]. Although the reason why so many sRNAs function through 5’
pairing remains unclear, it has been proposed that similar to eukaryotic microRNAs, some bacterial
sRNAs may have a 5’ conserved “seed” region that facilitates the selection for correct mRNA
targets (42). Thus, the OrzO sRNA likely uses the first 18 nt of its 5’ end as the “seed” region.
Further sequence analysis studies of a larger group of sRNAs and their targets will be helpful to
evaluate whether the existence of the “seed” region can be applied as a general principle in the
prediction of bacterial 5’ pairing sRNAs and their target mRNAs.
Recognition of zorO by the V1 region of OrzO We have shown specifically that the V1 region
of OrzO plays a crucial role in recognizing its target. Replacing the V1 region of OrzO with that
of OrzP abrogates the ability of the sRNA to repress the zorO mRNA, whereas replacing the V1
region of OrzP with that of OrzO allows the mutated OrzP to repress zorO.
When inspecting the predicted structures of OrzO and zorO (Figure 2.15A, 2.15B), we find
that both the V1 region of OrzO and the V1 target site in zorO are located in single-stranded
structures. The relatively relaxed property of these single-stranded structures may allow for
enhanced access of the single-stranded nucleotides to pair with their targets compared to those in
a stem structure. Thus, it is likely that the pairing between the V1 region of OrzO sRNA and the
corresponding site of zorO mRNA occurs prior to that of other complementary nucleotide regions.
In addition, when we mutated the bases of the V1 region, we noted that mutation of the
first nucleotide of the V1 region caused a complete loss of the repression of zorO without affecting
the levels of the sRNA. However, other single base mutants constructed in this study all
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successfully repress zorO (Table 2.3). These results suggested that as compared to other
nucleotides, pairing via the first nucleotide of the V1 region is most critical for the OrzO sRNA to
regulate zorO mRNA expression.
These observations suggest that OrzO and zorO may interact through a “kissing complex”.
Generally, in a “kissing complex”, the binding regions of the sRNA and the mRNA are located in
loop structures (single-stranded). The initial base pairing occurs at the short exposed regions; thus,
mutations of nucleotides involved the primary “kissing” region impact the repression outcome, as
exemplified by the RNAII-RNAI pair in ColE1-derived plasmid and the CopA-CopT pair in R1
plasmid (43,44). Once the initial pairing is established, the kissing complex can extend and
propagate the formation of double-stranded RNA in the rest of the sequence. Similarly, this has
been reported for the interaction of the ibs-Sib type I toxin-antitoxin pair in E. coli; however, in
this system, there are two recognition sites, in zorO-orzO, there appears to be only one recognition
domain (45).
While these previously described systems seem to corroborate the results of this study,
structure-probing and kinetic experiments need to be performed to validate the predictions and to
define the order of occurrence of base pairing in different regions.
Multiple factors contribute to the repression ability of Orz Antitoxin sRNAs function by base
pairing to their target mRNAs. To successfully repress the toxin mRNA, an adequate amount of
functional antitoxin sRNA is required. Otherwise, even if the sRNA is capable of repressing its
mRNA target, insufficient RNA levels will result in partial or complete loss of repression.
We observed this directly with our OrzO Δ3 mutant, the expression levels of which were
lowered when compared to full-length OrzO. Because all of our Orz constructs are under the
control of the same promoter (IPTG-inducible PLlac-O1), the decreased levels of the OrzO Δ3 are
likely due to accelerated degradation. When performing the rescue experiment using the OrzO Δ3
mutant, an initial repression of zorO was observed when we induced the toxin with 0.2% arabinose,
but this repression was not long lasting (Figure 2.13A). Because the antitoxin sRNA is induced 30
minutes prior to that of the toxin mRNA, it is likely that enough OrzO Δ3 sRNA had accumulated
to initially repress zorO; however, as the “pre-made” OrzO Δ3 was consumed through base pairing
with zorO, the newly produced OrzO Δ3 was not sustained at a high enough level to maintain zorO
repression. When the inducer concentration was decreased from 0.2% to 0.002% to reduce zorO
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levels, the OrzO Δ3 mutant was able to repress zorO, implying that the levels of the sRNA were
now sufficient for repression.
It is also likely that the structure and thus, specific nucleotide sequence, of OrzO
contributes as well to its functional ability. For example, several of our mutants showed reduced
expression levels at 1 mM IPTG when compared to the wild type at the same IPTG induction. As
stated, all of our OrzO constructs were controlled by the same inducible promoter, so transcription
should not be affected. Thus, it is more likely that these constructs are more unstable than wild
type OrzO. As shown in Figure 2.15, much of the 5’ end of OrzO (region of base pairing) is
predicted to be in a stem structure. Disruption of this long stem, even by a single nucleotide, may
impact overall stability of the sRNA. Further analysis of the effect of these mutations on the
structure and degradation of OrzO is needed to resolve this.
Aside from RNA levels, the base pairing potential of the Orz sRNA also contributes to its
ability to repress zorO. Our data show that 15 nt of continuous complementarity at 5’ end of OrzO
are sufficient for the repression of zorO mRNA, as represented by the OrzO Δ3 mutant. However,
unlike continuous base pairing, in which the pairing region of the sRNA perfectly matches the
target sequence, unpaired nucleotides would interrupt the formation of the sRNA-mRNA duplex,
affecting repression of the mRNA. Thus, it is likely that more base pairing interactions are needed
to compensate for the instability of the RNA duplex caused by the unpaired base(s). The OrzO
6(1)10(1) and 6(1)11 mutants support this theory. Both RNAs were produced at levels similar to
wild type OrzO, but only Orzo 6(1)11 was able to successfully repress ZorO toxicity. The main
difference between OrzO 6(1)10(1) and OrzO 6(1)11 comes from the total number of base pairing
interactions, 16 versus 17, respectively. Additionally, the OrzP V1 mutant (pairing: 5(1)12) also
successfully represses zorO. Combined, these data suggest that the total amount of pairing impacts
the repression ability, rather than specific positioning of nucleotides (outside the V1 region).
How does binding to the 5’ UTR repress zorO toxicity? The region of complementarity in the
zorO mRNA is located in its long 5’ UTR, approximately 73-91 nt upstream of the start codon.
How could binding to this region prevent zorO expression? It is important to note that regulation
of the type I toxins Hok and TisB by their respective antitoxins occurs through pairing far upstream
of the start codons (46,47). Translation of hok requires the translation of a small peptide (encoded
by mok) found within the 5’ UTR of the hok mRNA. The antitoxin, Sok, is complementary to mok,
50

and hence binding of the sRNA prevents translation of mok, and consequently, hok (47). For tisB,
its ribosome binding site is inaccessible due to its secondary structure. However, within its 5’ UTR
is a stand-by ribosome binding site; here the ribosome can bind, and as the structure breathes,
move to the true ribosome binding site for translating tisB. The antitoxin, IstR-1, has sequence
complementarity that overlaps the stand-by site; thus, formation of a tisB-IstR-1 RNA duplex
would prevent ribosome binding (46).
The zorO mRNA has 5’ UTR that is approximately 180 nt in length (Figure 2.1A); within
this UTR are several potential small open reading frames and ribosome binding sites. It is possible
that zorO translation is mediated in a manner similar to either hok or tisB, and that binding by
OrzO may block either translation of an internal peptide or binding of the ribosome to a stand-by
site. Ongoing experiments will help elucidate how binding of the antitoxin so far upstream from
the ATG start site successfully represses zorO expression.
Role of the zor-orz locus? A major question regarding many type I toxin-antitoxin loci is what is
their true biological function? This is particularly true for the chromosomally encoded loci. Work
has implicated the role of the type I toxin TisB in halting cell division during the SOS-response,
allowing the cell time to repair damaged DNA, as well as playing a role in persister cell formation
(48,49). Several of the type I loci described in B. subtilis exist on prophages [reviewed in (50)]. In
particular, txpA-ratA is located on the skin element, which is excised during sporulation (17). It
has been suggested that TxpA helps maintain the skin element within B. subtilis. For the BsrG/SR4
locus, data has shown that degradation of the bsrG toxin mRNA is accelerated under high
temperatures (16). How this may influence the function of the toxin has not yet been elucidated.
In the case of the zor-orz locus, it is not found beyond E. coli and Shigella species, and is
absent from laboratory strains of E. coli like MG1655 (14). This implies that the locus may have
been lost upon domestication of E. coli and perhaps the zor-orz locus is needed for growth in the
normal habitat of E. coli, the intestine. Furthermore, previous work showed that there are
differences in the chromosomal expression of zorO and orzO during growth with glucose as the
sole carbon source (14). We have confirmed that the endogenous expression of the sRNA and the
mRNA is sensitive to carbon source, implying a possible role for the locus in cellular metabolism
(Wen, Fozo, unpublished observations). Thus, the zor-orz locus may play a role in controlling
cellular growth in response to changing nutrient conditions in the native environment. Current
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work examining the effects of deleting the locus on total cellular metabolism and gene expression
are ongoing to decipher how these genes may impact overall cellular growth.
Overall, our data indicates that the 5’ end of OrzO is sufficient for repressing zorO; that
the V1 region dictates Orz sRNA specificity for its target; and that there appears to be a minimum
length required for base pairing. Further investigations are aimed at understanding the precise
regulatory mechanisms of this untraditional type I toxin-antitoxin system to better our
understanding of the intricacies of RNA regulation.
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Appendix II: chapter II tables and figures
Table 2.1. Strains and plasmids used in this study
Name
Escherichia coli EDL933
DJ480
UTK007
UTK008
UTK011

Relevant genotype or description
Wildtype EHEC, O157:H7
MG1655 ΔlacX74 (wild type strain)
DJ480 PCP18-araE
UTK007 Δhfq::kan
UTK007 Δrnc::kan

Source
D. Friedman
D. Jin, (20)
This study
This study
This study

KmR
AmpR; PLacO promoter
CmR; PBAD promoter
AmpR
CmR
AmpR
AmpR
AmpR
AmpR
CmR
AmpR
AmpR
AmpR
AmpR
AmpR
AmpR
AmpR
AmpR
AmpR
AmpR

(24)
(20)
(17)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Plasmids
pKD4
pBR-pLac
pEF21
pBR-pLac-orzO
pEF21-zorO
pBR-pLac-orzO-ohsC
pBR-pLac-orzO-istR
pBR-pLac-orzP
pBR-pLac-orzO V1
pEF21-zorO V1
pBR-pLac-orzP V1
pBR-pLac-orzO 8(1)9
pBR-pLac-orzO 10(1)7
pBR-pLac-orzO 9(1)8
pBR-pLac-orzOΔ3
pBR-pLac-orzOΔ6
pBR-pLac-orzO 5(2)11
pBR-pLac-orzO 6(1)11
pBR-pLac-orzO 6(1)10(1)
pBR-pLac-orzO 1(5)1(11)
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Table 2.2. Oligonucleotides used in this study
Sequencea

Name

Use

EF506

CCTGCTGGTGAGGCAGGTTCTTTTATTT

OrzO Northern analysis

EF511

GAGCACGGTTAACTTTTGTGTCAGCGTGT

zorO Primer extension analysis

EF517

CTACAGTGACGCTAACTTGCTGATT

OrzO Northern analysis

EF524

GTTGGTACGAAACGTTGCTCTCCG

zorO Northern analysis

EF769

CAGAATCGAAAGGTTCAAAGTACAAATAAGCATATAAGGAAAAGAGAGAATGAT
TGAACAAGATGGATTG

UTK008 PCR (Δhfq)

EF770

CGCAGGATCGCTGGCTCCCCGTGTAAAAAAAACAGCCCGAAACCTTAGAAGAACT
CGTCAAGAAG

UTK008 PCR (Δhfq)

EF771

GTCTGTTTCGTGTGCTGAATTGTTGACGCATTTATTTATTGGTATCGCATGATTGAA
CAAGATGGA

UTK011 PCR (Δrnc)

EF772

GATGGCAATAAATCCGCAGTAACTTTTATCGATGCTCATTCCAGCTCCAGTCAGAA
GAACTCGTCAAGAAG

UTK011 PCR (Δrnc)

EF537

GTGGATATGGTTATAATGACGTCGTTGTTACGAA

pBR-pLac-orzO PCR

EF538

GATGTGGAATTCTATGGTGGGCTATTGGC

pBR-pLac-orzO PCR; pBR-pLac-orzO-ohsC
PCR; pBR-pLac-orzO-istR PCR; pBR-pLacorzOΔ3 PCR, pBR-pLac-orzOΔ6 PCR

EF531

GAGATTTATAATCCTGCAGGTTGGGACGTTGC

pEF21-zorO PCR

EF532

GAGTTAAAGCTTGAATTAATAAAAACAGTAATC

EF78

GACACGGAAATGTTGAATAC

EF790

CTTTTTAACTTTAATTTTGCAACATTTCGTACCAACGACGTC

pEF21-zorO PCR
pBR-pLac-orzO-ohsC PCR; pBR-pLacorzO-istR PCR
pBR-pLac-orzO-ohsC PCR

EF791

GAAATGTTGCAAAATTAAAGTTAAAAAGTAAAACCCCCGTTCC

pBR-pLac-orzO-ohsC PCR

EF792

GCCACGGTAA GAATTC AAAGTTAAAAATAATACCG

pBR-pLac-orzO-ohsC PCR

EF793

GCGGCTGGTAACCGCAGCAACATTTCGTACCAACGACGTC

pBR-pLac-orzO-istR PCR

EF794

CGAAATGTTGCTGCGGTTACCAGCCGCGGGCGGCTGACG

pBR-pLac-orzO-istR PCR

EF795

CTGTACTGCAGAATTCAAAAAACCCCGCCGGAGCG

pBR-pLac-orzO-istR PCR
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Table 2.2. (continued)
Name
EF541
EF542
EF700
EF701
EF725
EF726
EF702
EF703
EF998
EF999
EF976
EF977
EF745
EF746
EF853
EF875
EF940
EF941
EF934
EF935
EF972
EF973
EF944
EF945

Sequencea
CCAGCCGTGGTTATAATGACGTCGTTGGAACACG
GTTGTTGAATTCAAAAATATCTGGG
CTGACGTCGTTGGTACACGATGTTGCACAATCAGC
GCTGATTGTGCAACATCGTGTACCAACGACGTCAG
GATCCGGAGAGCAACGTCGTGTACCAACATACGTAAAC
GTTTACGTATGTTGGTACACGACGTTGCTCTCCGGATC
CTGACGTCGTTGGAACGAAATGTTGCACAGGCTGTG
CACAGCCTGTGCAACATTTCGTTCCAACGACGTCAG
CTGACGTCGTTGGTACCAAATGTTGCACAATCAG
CTGATTGTGCAACATTTGGTACCAACGACGTCAG
GACGTCGTTGGTACGACATGTTGCACAATCAGCAAG
CTTGCTGATTGTGCAACATGTCGTACCAACGACGTC
CTGACGTCGTTGGTACGCAATGTTGCACAATCAGC
GCTGATTGTGCAACATTGCGTACCAACGACGTCAG
GGTTATAATTTA GACGTC GGTACGAAATGTTGCACAATC
GGTTATAATTTATTC GACGTC ACGAAATGTTGCACAATC
GATACTGACGTCGTTGGATCGAAATGTTGCACAATCAGC
GCTGATTGTGCAACATTTCGATCCAACGACGTCAGTATC
GATACTGACGTCGTTGGTTCGAAATGTTGCACAATCAGC
GCTGATTGTGCAACATTTCGAACCAACGACGTCAGTATC
CGTCGTTGGTTCGAAATGTTGACAATCAGCAAGTTAGCG
CGCTAACTTGCTGATTGTCAACATTTCGAACCAACGACG
GATACTGACGTCCTTGGTTCGAAATGTTGCACAATCAGC
GCTGATTGTGCAACATTTCGAACCAAGGACGTCAGTATC

Use
pBR-pLac-orzP PCR
pBR-pLac-orzP PCR
pBR-pLac-orzO V1 PCR
pBR-pLac-orzO V1 PCR
pEF21-zorO V1 PCR
pEF21-zorO V1 PCR
pBR-pLac-orzP V1 PCR
pBR-pLac-orzP V1 PCR
pBR-pLac-orzO 8(1)9 PCR
pBR-pLac-orzO 8(1)9 PCR
pBR-pLac-orzO 10(1)7 PCR
pBR-pLac-orzO 10(1)7 PCR
pBR-pLac-orzO 9(1)8 PCR
pBR-pLac-orzO 9(1)8 PCR
pBR-pLac-orzOΔ3 PCR
pBR-pLac-orzOΔ6 PCR
pBR-pLac-orzO 5(2)11 PCR
pBR-pLac-orzO 5(2)11 PCR
pBR-pLac-orzO 6(1)11 PCR
pBR-pLac-orzO 6(1)11 PCR
pBR-pLac-orzO 6(1)10(1) PCR
pBR-pLac-orzO 6(1)10(1) PCR
pBR-pLac-orzO 1(5)1(11) PCR
pBR-pLac-orzO 1(5)1(11) PCR

.

a

5' - 3', restriction sites underlined, nucleotides altered via site directed mutagenesis in red.
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Table 2.3. Summary of the mutants generated and their repressive abilities

sRNA

Target
mRNA

Repression ability

a

Total
number of
perfect base
pairing

Base
pairing
pattern

Base pairing
OrzO WT

OrzO WT

OrzO V1

OrzP WT

OrzP V1

OrzO Δ3

zorO WT

zorO WT

zorO WT

zorO WT

zorO WT

Full

No

No

Full

Repress zorO
induced by 0.002%
arabinose

18

16

15

17

15

5’ GUUGGUACGAAAUGUUGC 3’
||||||||||||:|||||

18
zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzO V1

5’ GUUGGUACACGAUGUUGC 3’
||||||||

8(2)8

:|:|||||

zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzP WT

5’ GUUGGAACACGAUGUUGC 3’
||||| ||

5(1)2(2)8

:|:|||||

zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzP V1

5’ GUUGGAACGAAAUGUUGC 3’
||||| ||||||:|||||

5(1)12
zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzO Δ3

5’

GGUACGAAAUGUUGC 3’
|||||||||:|||||

15
zorO WT

3’ CAACCAUGCUUUGCAACG 5’

61

Table 2.3. (continued)

sRNA

Target
mRNA

Total number
Base pairing
Repression abilitya of perfect base
pattern
pairing

Base pairing
OrzO Δ6

OrzO Δ6

OrzO 6(1)11

OrzO 5(2)11

OrzO (1)5(1)11

OrzO 6(1)10(1)

zorO WT

zorO WT

zorO WT

zorO WT

zorO WT

No

Full

No

No

No

12

17

16

16

16

5’

ACGAAAUGUUGC 3’
||||||:|||||

12
zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzO 6(1)11

5’ GUUGGUUCGAAAUGUUGC 3’

6(1)11

|||||| |||||:|||||
zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzO 5(2)11

5’ GUUGGAUCGAAAUGUUGC 3’
|||||

5(2)11

|||||:|||||

zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzO (1)5(1)11

5’ CUUGGUUCGAAAUGUUGC 3’

(1)5(1)11

||||| |||||:||||||
zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzO 6(1)10(1)

5’ GUUGGUUCGAAAUGUUGA 3’
|||||| |||||:||||

6(1)10(1)
zorO WT

3’ CAACCAUGCUUUGCAACG 5’
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Table 2.3. (continued)

sRNA

Target
mRNA

Repression ability

a

Total
number of
perfect base
pairing

Base
pairing
pattern

Base pairing
OrzO 10(1)7

OrzO 10(1)7

OrzO 9(1)8

OrzO 8(1)9

zorO WT

zorO WT

zorO WT

Full

ND

b

No

17

17

17

10(1)7

|||||||||| |:|||||
zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzO 9(1)8

5’ GUUGGUACGCAAUGUUGC 3’
||||||||| ||:|||||

9(1)8
zorO WT

3’ CAACCAUGCUUUGCAACG 5’

OrzO 8(1)9

5’ GUUGGUACCAAAUGUUGC 3’
|||||||| |||:|||||

8(1)9
zorO WT
OrzO V1

OrzO V1

zorO V1

Full

18

5’ GUUGGUACGACAUGUUGC 3’

3’ CAACCAUGCUUUGCAACG 5’
5’ GUUGGUACACGAUGUUGC 3’
||||||||||||:|||||

18
zorO V1

3’ CAACCAUGUGCUGCAACG 5’

a

Repression ability when zorO is induced by 0.2% arabinose unless otherwise indicated.

b

Despite generation of this mutant independently multiple times, we never obtained consistent results when analyzing its ability to

repress zorO induced either with 0.2 or 0.002% arabinose.
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Figure 2.1. The zorO-orzO gene locus is a true type I toxin-antitoxin system. (A) Genetic
organization of the duplicated zor-orz locus in E. coli EDL933. Sequence details of the zorO-orzO
genes; region of base pairing is shaded, and previously mapped transcription starts are indicated
in bold (14). Predicted -35 and -10 promoter elements are boxed. Black arrows indicate RNA
processing products found in both the wild type and Δrnc strain; green arrows, wild type strain
only; red arrows, Δrnc strain only. (B) Overexpression of OrzO can repress zorO-mediated toxicity.
E. coli strain UTK007 was transformed with pBR-plac-orzO (induced by IPTG) and pBAD-zorO
(induced by arabinose). The strain was grown to OD600 ≈ 0.1, and the culture was split into two.
IPTG (1 mM final concentration) was added to one half of the culture. Arabinose (0.2% final
concentration) was added 30 minutes later to each culture and OD600 was measured over time.
Solid symbols indicate the addition of IPTG; open symbols, no IPTG. Shown are the mean values
± standard deviations for three independent cultures. Predicted region of base pairing is shown.
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Figure 2.1. (continued)
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Figure 2.2. The RNA chaperone Hfq is not required for OrzO to repress zorO-induced
toxicity. E. coli wild type strain UTK007 (red) and E. coli strain UTK008 (blue), a derivative of
the wild type which is deleted for hfq, were transformed with pBR-plac-orzO and pBAD-zorO.
The strains were grown to OD600 ≈ 0.1, and split into two. IPTG (1 mM) was added to one half of
the culture. Arabinose (0.2%) was added 30 minutes later to each culture and OD600 was measured
over time. Solid symbols indicate the addition of IPTG; open symbols, no IPTG. Averages ±
standard deviations for three independent cultures are shown.
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Figure 2.3. RNase III is critical for OrzO repression of zorO. (A) Overexpression of OrzO
cannot repress zorO-mediated toxicity in a strain deleted for rnc. E. coli strain UTK011, which is
deleted for rnc, was transformed with pBR-plac-orzO and pBAD-zorO. The strain was grown to
OD600 ≈ 0.1, and split into three. One of the three cultures received no supplementation. IPTG (1
mM) was added as indicated to one culture. After 30 minutes, arabinose (0.2%) was added to two
of the cultures and cell growth was monitored by measuring the OD600 over time. Solid symbols
indicate the addition of arabinose and IPTG; open symbols, arabinose and no IPTG; no symbol
indicates unsupplemented culture. Shown are the averages ± standard deviations from three
independent experiments. (B) Accumulation of full-length zorO mRNA in the rnc deletion strain.
Total RNA was isolated from a wild type strain (UTK007) and an rnc deletion strain (UTK011)
harboring pBAD-zorO 0, 5, 15, 30, 60 minutes after the addition of 0.2% arabinose. Arrows
indicate the predicted full-length zorO transcripts.
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Figure 2.4. Effects of an rnc deletion on OrzO expression and processing of zorO. (A)
Expression of OrzO in a Δrnc strain. Total RNA was isolated as described in Materials and
Methods from a wild type strain (UTK007) and an rnc deletion strain (UTK011) harboring pBADzorO and pBR-plac-orzO. The antitoxin OrzO was induced with 1 mM IPTG, and RNA was
isolated 0, 5, 15, 30, 60 minutes after the addition of 0.2% arabinose. Average intensities are shown
as described in the Materials and Methods. (B) Processing of zorO in a wild type strain and a Δrnc
strain. RNA was isolated as described in the Materials and Methods 30 minutes after arabinose
addition ± induction of OrzO (1 mM IPTG). The sequencing gel was loaded twice; the panel on
the left was run longer, to allow better separation of the cleavage products closer to the start of
transcription. Black arrows indicate products found in both the wild type and Δrnc strain; green
arrows, wild type strain only; red arrows, Δrnc strain only. The black brackets indicate the
sequence region overlap of the two panels.
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Figure 2.5. The 5’ end of OrzO is sufficient for inhibition of zorO-mediated toxicity. (A)
Generation of an OrzO-OhsC and OrzO-IstR chimeras. The 5’ ends of the type I antitoxins OhsC
and IstR were replaced with the 5’ end of OrzO, the longest region of complementarity to zorO.
Underlined sequences indicate the OrzO nucleotides. (B) Overexpression of both OrzO-OhsC and
OrzO-IstR chimeras repress zorO. Rescue experiment was performed as outlined in Figure 2.1B
with either OrzO-OhsC (blue triangles) or OrzO-IstR (orange squares) expressed from the PLlacO-1
promoter of pBR-plac. Solid symbols indicate the addition of IPTG; open symbols, no IPTG. The
averages of three independent cultures ± standard deviations are shown. (C) Neither wild type
OhsC nor IstR can repress zorO-induced toxicity. Rescue experiment was performed with pBRplac-orzO (red circles), pBR-plac-ohsC (blue triangles), or pBR-plac-istR (orange squares) as
outlined in Figure 2.1B. Solid symbols indicate addition of IPTG; open symbols, no IPTG. Shown
are the averages ± standard deviations for three independent cultures.
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Figure 2.6. The V1 region is responsible for target discrimination by OrzO. (A) Alignment of
OrzO and OrzP sRNAs. The V1 region is indicated in the black box; the entire base pairing region
is in bold. (B) Potential base pairing interactions between OrzP and zorO in the predicted binding
region. (C) OrzO, not OrzP, can repress zorO. Rescue experiment was performed as outlined in
Figure 1B with either wild type OrzO (red circles) or OrzP (blue triangles) expressed from the
PLlacO-1 promoter of pBR-plac. Solid symbols indicate the addition of IPTG; open symbols, no
IPTG. Averages ± standard deviations of three independent cultures are shown. (D) An OrzP V1
mutant can rescue cells from zorO overexpression. Rescue experiment was performed as outlined
in Figure 2.1B using pBR-plac-orzP V1 (orange squares), in which its V1 region was mutated to
match OrzO, and pBR-plac-orzO V1 (blue triangles), in which its V1 was mutated to match OrzP.
Solid symbols indicate addition of IPTG; open symbols, no IPTG. Averages ± standard deviations
for three independent cultures are shown.
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Figure 2.7. OrzP expression levels are equivalent to OrzO expression levels. Total RNA was
isolated as described in Materials and Methods from UTK007 harboring pBAD-zorO and either
pBR-plac-orzO or pBR-plac-orzP after 0, 5, 15, 30, 60 minutes of induction with 0.2% arabinose.
Note that both OrzO and OrzP were induced by 1 mM IPTG.
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Figure 2.8. Restoration of the base pairing interactions between OrzO V1 to zorO prevents
zorO toxicity. The compensatory mutations were made in pBAD-zorO (Table 2.3) so that it could
perfectly base pair with OrzO V1. The resulting construct, pBAD-zorO V1 was transformed into
UTK007 harboring either pBR-plac-orzO (red circles) pBR-plac-orzO V1 (blue triangles) and a
rescue experiment was performed as outlined in Figure 2.1B. Solid symbols indicate addition of
IPTG; open symbols, no IPTG. Averages ± standard deviations for three independent cultures are
shown. Predicted base pairing interactions between OrzO V1 and zorO V1 are shown on the right.
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Figure 2.9. A specific residue within the V1 region of OrzO is necessary for zorO repression.
(A) Mutation of the first nucleotide of the V1 region fails to rescue E. coli from ZorO toxicity.
Rescue experiment was performed as outlined in Figure 2.1B except that arabinose was added to
a final concentration of 0.002%. Shown are the averages ± standard deviations of pBR-plac-orzO
(red circles) or pBR-plac-orzO 8(1)9 (blue triangles), which has the first nucleotide of the V1
region mutated. Solid symbols indicate addition of IPTG; open symbols, no IPTG. (B) Expression
of OrzO 8(1)9 is similar to wild type OrzO. Total RNA was isolated from E. coli UTK007
overexpressing zorO (0.002% arabinose) and either OrzO (1 mM IPTG) or OrzO 8(1)9 (1 mM
IPTG) as described in Materials and Methods. Quantification of RNA levels is described in the
Materials and Methods, with OrzO WT at T15 set to a value of 1. Numbers below the panel indicate
the average relative intensities. (C) Mutation of the third nucleotide of the V1 region has no impact
on the ability of OrzO to repress zorO expression. The third nucleotide of the V1 region of OrzO
was mutated to generate OrzO 10(1)7. A rescue experiment was performed as outlined in Figure
2.1B with wild type OrzO (red circles) or OrzO 10(1)7 (blue triangles) expressed from the PLlacO1

promoter of pBR-plac. Solid symbols indicate addition of IPTG; open symbols, no IPTG.

Averages ± standard deviations for three independent cultures are shown.
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Figure 2.9. (continued)
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Figure 2.10. Expression comparison of OrzO mutants to wild type OrzO. Quantifications of
the northern analysis of OrzO WT to OrzO 8(1)9 (A), OrzO Δ3 (B), OrzO Δ6 (C), OrzO 5(2)11
(D), OrzO (1)5(1)11 (E), or OrzO 6(1)10(1) (F). Note that the mutant sRNAs were induced with
1 mM IPTG, whereas the wild type was induced with either 1 mM (A) or 0.1 mM IPTG (B, C, D,
E, and F). The intensity of the band representing OrzO WT at T15 in each northern was set to a
value of 1. The relative intensities of the other bands in the same northern blot were thus calculated
and plotted in bar graph. Shown are the averages ± standard deviations from the mean values of
the three independent assays. *, P < 0.05 determined by Student’s t test.
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Figure 2.10. (continued)
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Figure 2.11. The ability of OrzO 9(1)8 to repress zorO-induced toxicity is variable. (A) Rescue
experiment was performed as outlined in Figure 2.1B using either pBR-plac-orzO or pBR-placorzO 9(1)8 as indicated. For co-expression of OrzO WT with zorO, 1 mM IPTG and 0.002%
arabinose (red circles) was used; for co-expression of OrzO 9(1)8 and zorO, 1mM IPTG and 0.2%
(orange squares) or 0.002% arabinose (blue triangles) were used. Solid symbols indicate addition
of IPTG; open symbols, no IPTG. Averages ± standard deviations for three independent cultures
are shown. (B) OrzO 9(1)8 is expressed at levels higher than the basal levels of wild type OrzO
needed to repress zorO. Total RNA was isolated from E. coli UTK007 overexpressing zorO (0.002%
arabinose) and either orzO WT (0.1 mM IPTG) or orzO 9(1)8 (1 mM IPTG) as described in
Materials and Methods. Average intensities are shown as described in the Materials and Methods.
(C) Quantification of the expression of OrzO 9(1)8 to wild type OrzO. Quantification of RNA
levels is described in the Materials and Methods, with OrzO WT at T15 set to a value of 1. The
relative intensities of the other bands in the same northern blot were thus calculated and plotted in
the bar graph. Shown are the averages ± standard deviations from the mean values of the three
independent assays. *, P < 0.05 determined by Student’s t test.
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Figure 2.11. (continued)
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Figure 2.12. The minimal level of OrzO needed for repression and the minimal amount of
zorO that can cause toxicity. (A) Overexpression of OrzO with 0.1mM IPTG fully represses
zorO-induced toxicity. Rescue experiment was performed as outlined in Figure 2.1B. Arabinose
was added to a final concentration of 0.002%; IPTG, 1 mM (red circles) or 0.1 mM (blue triangles).
Solid symbols indicate addition of IPTG; open symbols, no IPTG. Averages ± standard deviations
for three independent cultures are shown. (B) Levels of OrzO induced by 0.1mM IPTG versus 1
mM IPTG. Total RNA was isolated as described in Materials and Methods from E. coli UTK007
harboring pBAD-zorO and pBR-plac-orzO. Shown are samples 0, 5, 15, 30, 60 minutes post
induction with 0.002% arabinose and either 0.1mM or 1mM IPTG. Average intensities are shown
as described in the Materials and Methods. (C) Expression comparison of wild type OrzO induced
by 0.1 mM and 1 mM IPTG. Quantification of RNA levels is described in the Materials and
Methods, with OrzO WT induced by 0.1 mM IPTG at T15 set to a value of 1. The relative intensities
of the other bands in the same northern blot were thus calculated and plotted in bar graph. Shown
are the averages ± standard deviations from the mean values of the three independent assays. *, P
< 0.05 determined by Student’s t test. (D) Overexpression of zorO with 0.002% arabinose causes
cell stasis. E. coli strain UTK007 harboring pBAD-zorO was grown to OD600 ≈ 0.2, and the culture
was split into three. Arabinose, 0.2% (red circles), 0.002% (blue triangles) or no arabinose (no
symbols) were added and OD600 was measured over time. Averages ± standard deviations for three
independent cultures are shown. (E) Expression of zorO induced by either 0.2% or 0.002%
arabinose. Total RNA was isolated as described in Materials and Methods from E. coli UTK007
harboring pBAD-zorO and pBR-plac-orzO. Shown are samples 0, 5, 15, 30, 60 minutes post
induction with 1mM IPTG and either 0.2% or 0.002% arabinose.
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Figure 2.12. (continued)
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Figure 2.13. Only 15 nucleotides of continuous base pairing are required for OrzO
inhibition of zorO. (A) OrzO ∆3 prevents zorO-induced toxicity at low levels of arabinose.
Rescue experiment was performed as outlined in Figure 2.1B with OrzO ∆3 expressed from the
PLlacO-1 promoter of pBR-plac. Note that zorO was induced by either 0.2% (blue triangles) or
0.002% (orange squares). Solid symbols indicate addition of IPTG; open symbols, no IPTG.
Averages ± standard deviations for three independent cultures are shown. (B) Comparison of
RNA levels between wild type OrzO induced by 0.1mM IPTG and OrzO ∆3 induced by 1mM
IPTG. Total RNA was isolated from E. coli UTK007 overexpressing OrzO or OrzO ∆3 from
pBR-plac as described in Materials and Methods. Average intensities are shown as described in
the Materials and Methods. (C) OrzO ∆6 fails to repress zorO-induced toxicity even at low levels
of arabinose induction. Rescue experiment was performed using either pBR-plac-orzO (red
circles) or pBR-plac-orzO ∆6 (blue triangles) as indicated. Note that the arabinose concentration
used was 0.002%. Solid symbols indicate addition of IPTG; open symbols, no IPTG. Averages ±
standard deviations for three independent cultures are shown. (D) Comparison of RNA levels
between the wild type OrzO induced by 0.1mM IPTG and the OrzO ∆6 mutant induced by 1mM
IPTG. Total RNA was isolated from E. coli UTK007 overexpressing OrzO or OrzO ∆6 from
pBR-plac as described in Materials and Methods. Average intensities are shown as described in
the Materials and Methods.
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Figure 2.13. (continued)
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Figure 2.14. Repression of zorO requires 17 nucleotides of discontinuous base pairing. (A)
OrzO 5(2)11 fails to inhibit ZorO toxicity. Rescue experiment was performed as outlined in Figure
2.1B with either wild type OrzO (red circles) or OrzO 5(2)11 (blue triangles) expressed from the
PLlacO-1 promoter of pBR-plac. Solid symbols indicate addition of IPTG; open symbols, no IPTG.
Averages ± standard deviations for three independent cultures are shown. (B) Comparison of RNA
levels between the wild type OrzO induced by 0.1mM IPTG and the OrzO 5(2)11 mutant induced
by 1mM IPTG. Average intensities are shown as described in the Materials and Methods. (C)
OrzO 6(1)11 can repress zorO. Rescue experiment was performed as outlined in Figure 2.1B with
either wild type OrzO (red circles) or OrzO 6(1)11 (blue triangles) expressed from the PLlacO-1
promoter of pBR-plac. Solid symbols indicate addition of IPTG; open symbols, no IPTG.
Averages ± standard deviations for three independent cultures are shown. (D) Neither OrzO
6(1)10(1) nor OrzO (1)5(1)11 can prevent zorO-induced toxicity. Rescue experiment was
performed with pBR-plac-orzO (red circles), pBR-plac-orzO (1)5(1)11 (blue triangles), or pBRplac-orzO 6(1)10(1) (orange squares). Note that IPTG was added to 1mM final concentration and
arabinose was added to 0.002% final concentration. Solid symbols indicate addition of IPTG; open
symbols, no IPTG. Averages ± standard deviations for three independent cultures are shown. (E)
Comparison of RNA levels between the wild type OrzO induced by 0.1mM IPTG and the OrzO
(1)5(1)11 mutant induced by 1mM IPTG. Average intensities are shown as described in the
Materials and Methods. (F) Comparison of RNA levels between the wild type OrzO induced by
0.1mM IPTG and the OrzO 6(1)10(1) mutant induced by 1mM IPTG. Average intensities are
shown as described in the Materials and Methods.
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Figure 2.14. (continued)
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A.

B.

Figure 2.15. Predicted secondary structures of zorO mRNA and OrzO indicate the V1 regions
are mostly single-stranded. (A) Putative RNA structure of zorO mRNA generated by M-fold
(http://http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form) (51). The black bracket
indicates the region of complementarity to OrzO; red brackets the putative ribosome binding site;
green bracket, the start codon. The black box is the V1 region binding site. (B) Putative RNA
structure of OrzO sRNA generated by M-fold (http://mfold.rna.albany.edu/?q=mfold/RNAFolding-Form) (51). The sequence indicated by the black bracket is the region of complementarity
to the zorO mRNA; the black box is the V1 region.
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CHAPTER III

5’ UTR inhibits and enhances translation of the type I toxin ZorO
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Publication note
This chapter is in preparation for submission. The tentative title is:
Jia Wen, John R. Harp, and Elizabeth M. Fozo. The 5’ UTR of the type I toxin ZorO can
both inhibit and enhance translation [In preparation].
My contribution to this paper was mutant constructions, toxicity assays, rescue experiments,
RNA isolation, northern analysis, in vitro transcription, structural probing, in vitro translation,
literature review, and writing. John R. Harp assisted in generating data presented in Figure 3.2,
where he performed the flow cytometry analyses. I performed all other experiments.
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Abstract
Many bacterial type I toxin mRNAs possess a long 5’ untranslated region (UTR) that can serve as
the target site of the corresponding antitoxin sRNA. This is the case for the zorO-orzO type I
system where the OrzO sRNA antitoxin base pairs to the 174-nucleotide zorO 5’ UTR. Here, we
demonstrate that the 5’ UTR of the zorO type I toxin controls zorO translation independent of the
sRNA such that the full-length 5’ UTR hinders translation whereas a processed 5’ UTR (zorO ∆28)
promotes translation. The full-length zorO 5’ UTR folds into an extensive secondary structure
sequestering the ribosome binding site (RBS). Processing of the 5’ UTR does not alter the RBS
structure, but exposes a single-stranded region which we designate as the EAP (Exposure After
Processing) region located upstream of the RBS, which likely serves as a ribosome standby site.
Truncation of this EAP region severely impairs zorO translation, but this defect can be rescued by
exposure of the RBS. In addition to the EAP region, another region spanning +35 to +50 of the
zorO mRNA also facilitates translation and is needed for optimal translation of zorO. Importantly,
the positive and negative effects on translation imparted by the 5’ UTR can be transferred onto a
reporter gene, indicative that the 5’ UTR can solely drive regulation. Moreover, we show that the
cognate OrzO sRNA can inhibit zorO translation via base pairing to the 3’ end of the EAP region.
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I. Introduction
Across bacterial species, numerous toxin-antitoxin loci have been identified that are believed to
function in stress responses. These two-gene loci are categorized by both the nature of the antitoxin
and the mode of its action to repress the toxin. For a type I toxin-antitoxin locus, one gene encodes
a small protein that is toxic when overproduced and the second gene encodes a small RNA (sRNA)
that represses toxin production through base pairing [reviewed in (1)]. Most type I toxins share
common biochemical features: they usually contain a single putative transmembrane domain and
are hypothesized to function at the cytoplasmic membrane. Overproduction of type I toxins is
detrimental to bacterial cells and results in growth stasis or cell death. For instance, overexpression
of either the ibsC or shoB toxin gene in Escherichia coli inhibited cell growth and led to rapid
membrane depolarization (2). Further, TisB toxin overproduction in E. coli caused similar
membrane damage along with a dramatic decrease in cellular ATP levels (3). Additionally, some
type I toxins can impair nucleoid segregation and cell division prior to damaging the cell
membrane, as exemplified by the Fst toxin of Enterococcus faecalis (4).
Given its inherent toxicity, the production of a type I toxin must be tightly controlled. This
can be achieved through regulation by its corresponding antitoxin sRNA. More specifically, the
antitoxin sRNA base pairs with the toxin mRNA and inhibits translation of the mRNA and/or
stimulates the degradation of the mRNA, thereby preventing toxin production. This is exemplified
by the symE-symR locus of E. coli (5) in that the SymR sRNA base pairs to the translation initiation
region of the symE mRNA and blocks its translation, therefore repressing SymE production (6).
Further, in the txpA-ratA pair of Bacillus subtilis, base pairing of the RatA sRNA to the txpA
mRNA leads to RNase III-dependent degradation of txpA, rendering it untranslatable (7,8).
Aside from the sRNA antitoxin mediated regulation, production of some type I toxins can
be modulated by the 5’ untranslated regions (UTRs) of the toxin mRNAs themselves, particularly
for those toxin mRNAs that possess long and structured 5’ UTRs [reviewed in (9)]. One well
studied example is the type I toxin gene hok of plasmid R1 in E. coli (10). The hok mRNA has a
177-nt-long 5’ UTR, which harbors a small leader gene termed mok (11). Translation of the hok
mRNA is dependent upon translation of mok; however, the 5’ UTR of hok forms into a secondary
structure that occludes the mok RBS, preventing not only its translation but also that of Hok (12,13).
Although translation of the type I toxin TisB is also repressed by its long 5’ UTR, the underlying
mechanism is distinct from that of hok. In this case, the tisB RBS is structurally sequestered and
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translation of the tisB mRNA requires a single-stranded standby site upstream of the RBS that
allows ribosomes to preload onto the mRNA (14). This standby site, though, is occluded in a stem
structure and only becomes accessible upon processing of the 5’ UTR; thus, the full-length tisB
mRNA is translationally inactive.
We previously reported that the zorO-orzO gene pair in E. coli O157:H7 (EHEC) is a true
type I toxin-antitoxin locus, with zorO encoding the toxic small protein and orzO encoding the
antitoxin sRNA (15,16). The zorO mRNA has a long 5’ UTR of 174 nts with the region of base
pairing to OrzO located 60 nts upstream of the zorO RBS. When examining the predicted structures
of the zorO mRNA, we noted that the RBS is located in a stem structure (15), which could prevent
ribosomal access. We hypothesized that translation of zorO may require ribosomal preloading onto
a standby site to compensate for the closed RBS. Thus, disruption of this putative ribosome standby
site of zorO would impair translation of the zorO mRNA and alleviate the toxic effects of zorO
overexpression.
In this study, we confirm that the zorO RBS is occluded in stem structure and that
processing of the 5’ end is required for efficient translation. The 5’ processing does not alter the
structure at the RBS, but leads to the opening of a putative standby site (EAP region) that promotes
translation. Optimal translation of zorO requires not only the EAP region, but also another region
spanning from +35 to +50 of zorO 5’ UTR. Moreover, we demonstrate that the OrzO sRNA affects
both the stability and the translation of the zorO mRNA via base pairing at the EAP region of zorO,
therefore inhibiting the production of ZorO toxin.

II. Materials and Methods
Bacterial strains and plasmids The strains and plasmids used in this study are listed in Table 3.1,
and the sequences of all oligonucleotides are given in Table 3.2.
Growth conditions E. coli strains were grown in Luria–Bertani (LB) medium at 37°C with
shaking. For strains carrying pAZ3-zorO Δ28 or pAZ3-zorO Δ34, 0.2% glucose was added to
reduce leaky expression of the PBAD promoter. Antibiotics were used at the following
concentrations when needed: ampicillin, 100 µg/ml; chloramphenicol, 25 µg/ml; kanamycin, 25
µg/ml. Arabinose was added to a final concentration of 0.2%, 0.0001%, or 0.00001% as indicated.
When used, IPTG was added to a final concentration of 1 mM.
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Plasmid construction For overexpression of the zorO gene under the PBAD promoter, the full 5’
UTR of zorO along with the coding region was amplified from E. coli O157:H7 EDL933 genomic
DNA, digested with EcoRI and HindIII, and cloned into the corresponding sites of pAZ3 (5),
generating pAZ3-zorO. The pAZ3-zorO Δ28, pAZ3-zorO Δ34, pAZ3-zorO Δ50, and pAZ3-zorO
Δ82 were constructed in the same fashion. The pEF21-zorO ∆28 was generated following the same
scheme, but using a lower copy number vector pEF21 (pBAD33 derivative, pACYC origin) (2).
The pAZ3-zorO ∆82 RBS was constructed through site-directed mutagenesis as previously
described using pAZ3-zorO ∆82 as template (17).
For in vitro transcription assays, the full 5’ UTR of zorO along with the coding region was
amplified from E. coli O157:H7 EDL933 genomic DNA, digested with EcoRI and SmaI, and
cloned into the corresponding sites of pGEM®-3Zf(+) Vector (Promega), generating pGEM-T7zorO. Plasmids pGEM-T7-zorO ∆50, and pGEM-T7-zorO ∆82 were generated in the same
manner. The pGEM-T7-zorO ∆82 RBS was generated through site-directed mutagenesis using
pGEM-T7-zorO ∆82 as template.
The translational gfp fusion to zorO was generated using SOE PCR (18). PCR product A
amplified the full length 5’ UTR and the start codon of zorO from genomic DNA along with an
additional 18 nts at the 3’ end that overlapped with the PCR product B. PCR product B was the
result of amplifying the coding sequence of gfp from vector pFA6a-GFP(S65T)-kanMX6 (19).
The two products were spliced together using the external primers, digested with EcoRI and
HindIII, and cloned into the corresponding sites of pAZ3, generating pAZ3-zorO UTR-gfp. The
pAZ3-Δ28 UTR-gfp was constructed through amplifying the corresponding UTR-gfp region using
pAZ3-zorO UTR-gfp as template via PCR, and cloned into pAZ3.
Overproduction of toxic proteins ZorO toxicity assays were performed as described previously
(15). Briefly, the indicated pAZ3 plasmid was transformed into UTK007 via electroporation (20).
The resulting transformants were grown overnight and then diluted to an OD600 of 0.01. When the
OD600 reached 0.2 - 0.3, the culture was split and arabinose was added to half of the culture to a
final concentration of 0.2%, 0.0001%, or 0.00001%. Prior to arabinose induction, cells harboring
either pAZ3- zorO Δ28 or pAZ3- zorO Δ34 were washed twice with 1×phosphate-buffered saline
(PBS) and resuspended in LB medium to ensure no carryover of glucose. OD600 was measured
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every 30 min. Shown are averages ± standard deviations for a minimum of three independent
experiments.
Rescue experiments Rescue experiments were conducted as described previously (15,21). The
pBR-plac plasmid carrying the orzO gene under an IPTG-induced PLlacO-1 promoter was
transformed into UTK011 (∆rnc) through electroporation. Afterwards, the pEF21 plasmid
containing the full-length 5’ UTR of zorO and its coding sequence (zorO full-length) or the
processed 5’ UTR of zorO and its coding sequence (zorO ∆28) under the PBAD promoter was
transformed into the same cells. The resulting transformants harboring the two plasmids were
grown overnight and then diluted to OD600 of 0.01. When the OD600 reached ≈ 0.1, the cultures
were split and IPTG was added to half the culture to a final concentration of 1 mM. Thirty minutes
after IPTG induction, arabinose was added to a final concentration of either 0.0001% or 0.00002%
for the overproduction of zorO. OD600 was measured every 30 min. Shown are averages ± standard
deviations for a minimum of three independent experiments.
RNA extraction To compare the RNA levels of zorO wild type versus zorO mutants, cells carrying
the appropriate plasmid were grown as indicated in the toxicity assays to an OD600 ≈ 0.2 – 0.3, and
arabinose (0.2% or 0.0001%) was added (time 0). Cells were harvested at time 0, 5, 15, 30, and 60
min post-arabinose induction and total RNA was isolated via hot acid-phenol or direct lysis as
described previously (21,22). When needed, RNA was treated with TURBO™ DNase (Life
Technologies) following the manufacturer’s instructions.
Northern analysis Total RNA (10 µg) was separated on a denatured 6% polyacrylamide-urea gel
for detection of zorO wild type or mutant mRNA and transferred to a Zeta-Probe Genomic GT
membrane (Bio-Rad). Specific oligonucleotide probes were 5’ end-labeled with ɣ-32P by T4
polynucleotide kinase (New England Biolabs). Hybridization and washes of the membrane were
performed as described previously (23). Northern analysis was conducted from a minimum of
three independent experiments for every construct examined.
Flow cytometry analysis Cells containing a translational gfp fusion to zorO were grown as
previously indicated to an approximate OD600 ≈ 0.3 and split into two cultures. One culture was
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induced with 0.2% arabinose and the other served as a control. After the cultures were split,
aliquots were taken from the cultures at 0, 30, and 60 min. Due to cellular growth, 50 µl aliquots
were taken at time 0 and 25 µl aliquots were taken at time 30 and 60. These aliquots were flooded
with 4 ml of 1X PBS and washed extensively twice. Cells were resuspended in 1ml 1X PBS and
analyzed by flow cytometry in a LSR II flow cytometer (Becton Dickinson) with a 488-nm laser.
Samples were run at an event rate of 3,000 events per second. Green fluorescence was collected
in the fluorescein isothiocyanate (FITC) channel. Differences in fluorescence intensity of the
induction group versus the control group were obtained using geometric mean fluorescence for n
= 3.
In vitro transcription T7 in vitro transcription was conducted as described previously (24) with
modifications. Briefly, pGEM-T7-zorO or its derivatives was linearized with SmaI, purified using
the Qiagen PCR Purification Kit, and 1 µg of digested plasmid was used as the DNA template for
T7 transcription. A DNA template for zorO ∆28 mRNA was amplified from E. coli O157:H7
EDL933 genomic DNA via PCR with primers containing the T7 promoter. The DNA template,
ribonucleotides (each at 2 mM, New England Biolabs), 8 mM DTT (Invitrogen), and 100 U T7
RNA polymerase (50 U/µl, New England Biolabs) were mixed in a 50 µl volume and incubated at
37°C for 16 hrs. Afterwards, 2 U of TURBO™ DNase (2 U/µl, Life Technologies) was added to
the transcription reaction, followed by incubation at 37°C for an additional 15 min. Transcribed
RNAs were then precipitated and gel purified (25).
RNA radiolabeling and in vitro structure probing For 5’ end labeling, the RNAs synthesized
from T7 transcription were dephosphorylated and end-labeled with ɣ-32P by T4 polynucleotide
kinase (New England Biolabs). For 3’ end labeling, RNAs were labeled with [5- ɣ 32P] pCp and
T4 RNA Ligase 1 (New England Biolabs).
In vitro structure probing was conducted in 10 µl reactions as described previously (26).
Radiolabeled zorO RNA and its derivatives (0.2 pmol) were denatured at 95°C for 1 min and
incubated on ice for 5 min, followed by the addition of 1 × Structure Buffer (Ambion) and 0.1
µg/µl yeast RNA. Unlabeled OrzO sRNA (250 nmol or 500 nmol) was added as indicated. The
reaction mixtures were incubated at 37°C for 1 h. For enzymatic probing, 2 µl of RNase T1 (0.01
U/µl; Ambion) were added and the samples were incubated for 6 min at 37°C. For chemical
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probing, 2 µl of fresh lead(II) acetate (25 mM) were added to corresponding reactions and
incubated for 1.5 min at 37°C. Reactions were stopped with the addition of 20 µl of
Inactivation/Precipitation buffer (Ambion) mixed by vortexing, and precipitated. The RNA pellets
were suspended in 7 µl Loading Buffer II (95% formamide, 18 mM EDTA, 0.025% SDS, 0.2%
xylene cyanol, 0.2% bromophenol blue; Ambion).
To generate the RNase T1 ladder, radiolabeled RNA (0.4 pmol) was mixed with 1 ×
Sequencing Buffer (Ambion), denatured at 95°C for 1 min, and chilled on ice for 5 min. The
mixture was incubated with RNase T1 (1 µl, 0.1 U/µl) at 37°C for 5 min, and 12 µl of loading
buffer II was added to stop the reaction. To generate the hydroxyl ladder, radiolabeled RNA (0.4
pmol) was mixed with 1 × Alkaline Hydrolysis Buffer (Ambion) and incubated at 90°C for 5 min.
The reaction was stopped with the addition of 12 µl of loading buffer II.
All samples were denatured at 95°C for 3 min and 3 µl of each sample was resolved on a
denatured 6% polyacrylamide-urea gel. Gels were dried and then exposed to BioMax XAR film
(Kodak).
In vitro translation In vitro translation was performed using E. coli S30 Extract System (Promega)
as described previously with modifications (14). Briefly, 0.1 µM or 0.25 µM of in vitro transcribed
zorO RNA was mixed with 0.2 mM 35S-labelled methionine (>1000 Ci/mmol, PerkinElmer), 7.5
µl S30 extract, 10 µl S30 premix without amino acids, and 0.1 mM of each amino acid minus
methionine. 5 µM of orzO RNA were added as indicated in the text. The reactions were incubated
at 37°C for 30 min and chilled on ice for 5 min. For each reaction, 5 µl aliquots were mixed with
20 µl cold acetone and incubated on ice for an additional 15 min. Afterwards, the reaction mixtures
were centrifuged for 10 min at 4°C at 12,000 g. The protein pellets were suspended in 15 µl of
H2O, mixed with 4X Bolt LDS sample buffer (Life Technologies), and resolved on NuPAGE
Novex 4-12% Bis-Tris Plus Gels in MES Buffer (Life Technologies) alongside SeeBlue® PreStained Protein Standard (Life Technologies). Gels were fixed in methanol/acetic acid solution
(45% methanol, 10% acetic acid) for 30 min at room temperature and washed in 100 ml Amplify
Fluorographic Reagent solution (GE Healthcare) for 60 min. Gels were subsequently dried and
exposed to BioMax XAR film (Kodak).
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III. Results
5’ processed form of zorO exhibits more efficient translation Previous primer extension
analysis of the zorO mRNA revealed a major processed form at the + 29 from the transcription
start site (15). It has been shown that 5’ processing of some type I toxin mRNAs increases
translation of the mRNA [reviewed in (9)]. Thus, we hypothesized that the processed form of zorO
may be translated more efficiently than the full-length zorO.
To test if processing of the zorO mRNA impacts its translation, we constructed a zorO ∆28
mutant under the control of the PBAD promoter in the plasmid pAZ3 (pAZ3-zorO ∆28) in which
the first 28 nts of the zorO 5’ UTR were removed (Figure 3.1A). This mutant reflects the native
processed form of the zorO transcript. We predicted that if 5’ processing of the zorO mRNA
promotes zorO translation, the zorO Δ28 mutant would have a higher translation efficiency and
exhibit a more pronounced toxic phenotype than the zorO full-length under the same induction
condition.
To compare the toxicity of the zorO full-length and zorO ∆28 plasmids, we first determined
that 0.0001% was the lowest amount of arabinose needed to induce stasis in cultures overproducing
the full-length zorO mRNA (Figure 3.1B). Decreased levels of arabinose (i.e. 0.00001%) did
impact growth, but complete stasis was not observed (Figure 3.1B). On the contrary, zorO ∆28
still caused complete cell growth stasis at 0.00001% (Figure 3.1C). Given that the zorO coding
sequence remains unchanged in zorO ∆28, this “hypertoxic” phenotype observed is indicative of
increased production of ZorO toxin.
Since both the zorO full-length and the zorO ∆28 constructs examined above share the
same promoter and coding sequence, the more pronounced toxic phenotype caused by zorO ∆28
is likely not due to increased transcription or protein stability. Rather, it could be due to greater
RNA stability and/or higher translation efficiency. If the zorO ∆28 RNA is more stable, we would
expect to see increased RNA levels compared to that of the zorO full-length under the same
induction conditions. To test this, we examined the mRNA levels of the zorO full-length as well
as the zorO ∆28 by northern blot analyses. As shown in Figure 3.1D, zorO ∆28 was expressed at
levels equivalent to or even lower than the zorO full-length under the same induction condition.
This suggested that the elevated toxic phenotype of the zorO Δ28 mutant is likely due to increased
translation of the mRNA and not due to improved mRNA stability. To directly compare the
translation efficiency of zorO full-length versus zorO ∆28, an in vitro translation assay was
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performed. Although both were translated, the zorO ∆28 mRNA was more robustly translated than
the zorO full-length (Figure 3.1E). Therefore, the 5’ processing of zorO mRNA facilitates the
translation of zorO.
Enhanced translation by 5’ processing can be applied to another system We next wanted to
determine if the observed translational enhancement upon processing was due to changes in the 5’
UTR. If changes in the UTR drove the effects on translation, then the transfer of the zorO 5’ UTR
onto another gene would mimic the above results. To test this, we generated two translational gfp
fusions with either the full-length UTR (zorO UTR) or the processed UTR (∆28 UTR); both
fusions were under control of the PBAD promoter. We compared the production of GFP following
arabinose induction using flow cytometry. Without induction, these two constructs showed similar
background fluorescence throughout all time points taken (Figure 3.2A). Thirty minutes postinduction, however, the ∆28 UTR-gfp showed a dramatic increase (~8 fold) in fluorescence
intensity as compared to its uninduced control, whereas the fluorescence intensity of the full-length
UTR-gfp was similar to the control. Further, after 60 minutes, the fluorescence produced by cells
overexpressing the ∆28 UTR-gfp was 20 fold greater than its control, while the fluorescence
produced by cells overexpressing the full-length UTR-gfp was only 1.5 fold greater than its control
(Figure 3.2B and 3.2C). Additionally, we noted the full-length UTR-gfp was processed (data not
shown) similarly as we have noted for zorO (15) indicating that processing can occur regardless
of the downstream coding sequence. These results fully recapitulate the observed “hypertoxic”
phenotype of zorO ∆28 and confirm our findings that processing of the zorO 5’ UTR promotes
translation.
Opening of the +73 to +102 region in zorO ∆28 Our data suggested that removal of the first 28
nts of the 5’ UTR promotes zorO translation, yet the mechanism underlying this increased
translation remained unclear. The RBS of the zorO mRNA is predicted to be in a stem structure
that may impede ribosome binding (15,27). This raised the possibility that the 5’ processing could
lead to an overall rearrangement of the structure of the mRNA, rendering the RBS more accessible.
We thus employed in vitro structure probing to compare the zorO full-length and zorO ∆28
structures. Surprisingly, no structural differences were detected at the RBS or the flanking regions
of the zorO full-length and zorO ∆28 and both RBSs were in stems (Figure 3.3A and 3.3B). This
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indicates that the increased translation efficiency of zorO ∆28 was not due to a more accessible
RBS.
When comparing the two RNA structures, the only major difference we observed was in
the region spanning from the +73 to +102 from the transcription start site (Figure 3.3C). This
region was single-stranded in zorO ∆28 but was highly structured in the full-length zorO mRNA,
matching the structural predictions (15,27). Thus, processing of the 5’ end exposes this +73 to
+102 region, which we refer to as the EAP (Exposure After Processing) region. Interestingly, the
EAP region encompasses the zorO base pairing region by the antitoxin sRNA OrzO (Figure 3.3D)
(15). This indicates that the EAP region may also be involved in sRNA dependent posttranscriptional regulation of zorO (see below).
Disruption of the EAP region impairs zorO translation Since the EAP region is located
upstream (~ 100 nts) of the zorO RBS, we wanted to determine how exposure of this region
impacted translation. Given that the RBS of zorO is structurally sequestered, direct ribosomal
access to the RBS seems unlikely. Therefore, we hypothesized that optimal translation of zorO
may require a ribosome standby site to facilitate ribosome preloading onto the mRNA. Data
suggests that a standby site may not consist of a specific sequence, but instead is usually singlestranded (28). Owing to the single-stranded nature of the EAP region in zorO ∆28, we predicted
that it may serve as a standby site. We thus generated a truncated EAP mutant by deleting the first
82 nts of the zorO 5’ UTR (zorO ∆82) while maintaining the portion of the EAP region where the
OrzO sRNA base pairs (Figure 3.1A). If the EAP region serves as a standby site, truncation of this
region would interfere with ribosomal preloading and the subsequent translation, rendering the
zorO ∆82 less toxic than the zorO full-length.
Indeed, the zorO ∆82 mutant was not toxic when induced by 0.0001% arabinose in contrast
to full-length zorO (Figure 3.4A). Even when induced with saturating amounts of arabinose (0.2%),
zorO ∆82 only showed impaired cell growth (Figure 3.4B). Further, within 15 minutes of induction
of the full-length zorO with 0.2% arabinose, no viable colonies were detected via plating. However,
viable colonies were still detectable after 2 hours of induction of the zorO ∆82 using the same
arabinose concentration (0.2%; data not shown). Taken together, these data suggested that cells
overexpressing zorO ∆82 produced less ZorO toxin as compared to those overexpressing fulllength zorO.
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To separate out the effect of RNA stability from that of translation efficiency, we
determined the RNA levels of zorO ∆82 and zorO full-length by northern analysis. When both
were induced with 0.2% arabinose, the levels of zorO Δ82 mRNA was lower than that of zorO
full-length (data not shown), indicating that zorO ∆82 is less stable. We did note, though, that the
levels of zorO ∆82 induced by 0.2% arabinose were equivalent to that of zorO full-length induced
by 0.0001% arabinose (Figure 3.4C). However, despite the similar RNA levels, expression of only
the zorO full-length mRNA and not zorO ∆82, conferred full cell growth stasis (Figure 3.4A and
3.4B). This suggested that in addition to decreased RNA stability, zorO ∆82 was not translated as
efficiently.
To test whether the decreased toxicity was due in part to decreased translation of the zorO
∆82, we performed in vitro translation utilizing equal amounts of zorO full-length and zorO ∆82
mRNAs. As shown in Figure 3.4D, translation of the zorO ∆82 mRNA was barely detectable as
compared to the zorO full-length. Together, these data suggest that disruption of the EAP region
impairs translation efficiency.
Exposing the RBS rescues the translational defect of zorO ∆82 A standby site is thought to
increase the concentration of ribosomes around the RBS (14,29). As a result, when the RBS is
transitionally exposed, the preloaded ribosomes can rapidly initiate translation. In line with this,
we hypothesized that increased accessibility of the zorO RBS would obviate the need for a standby
site. We thus disrupted the RBS-containing stem in the zorO ∆82 mRNA by mutating the region
that base pairs with the zorO RBS (Figure 3.1A). This resulted in a zorO mutant that harbors a
constitutively exposed RBS (zorO ∆82 RBS). The zorO ∆82 RBS mutant was far more toxic than
the parental zorO ∆82 and its toxicity mirrored that of the full-length zorO when induced by 0.0001%
arabinose (Figure 3.5A). Additionally, northern blot analysis revealed that the zorO ∆82 RBS was
expressed at much lower levels than zorO full-length (Figure 3.5B), suggesting that the restored
toxicity seen in the zorO ∆82 RBS mutant was due to more efficient translation. This was further
supported by the results of the in vitro translation assay shown in Figure 3.4D. Taken together, our
data support the hypothesis that the EAP region of the zorO mRNA functions to compensate for a
closed zorO RBS.
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An additional element in zorO that affects zorO translation efficiency Our data indicate that
the EAP region facilitates the translation of zorO. Since the zorO mRNA harbors a long (174 nts)
and extensively structured 5’ UTR, we next wanted to examine if other regions of the 5’ UTR
contribute to zorO translation. We thus constructed two additional zorO mutants in which either
the first 34 nts (∆34) or 50 nts (∆50) from the transcription start site were deleted (Figure 3.1A).
They were subjected to the same toxicity assays and northern blot analyses as described above.
The zorO ∆34 mutant was similar to the aforementioned zorO ∆28 mutant in that it exhibited a
hypertoxic phenotype and the RNA levels were lower than the full-length zorO under the same
induction conditions (Figure 3.6A, 3.6B). This suggested that the translation efficiency of zorO
∆34 is also higher than that of zorO full-length.
Interestingly, the zorO ∆50 mutant showed a decreased toxic phenotype as compared to
the full-length when induced by 0.0001% arabinose (Figure 3.6C). Northern blot analysis indicated
that zorO ∆50 was expressed at levels similar or even higher to that of the full-length, suggesting
that the decreased toxicity was not due to differences in RNA levels (Figure 3.6D). When
compared to the full-length zorO mRNA, there was a moderate reduction in ZorO protein
production from the zorO ∆50 mRNA in vitro (Figure 3.6E). These data suggested that the zorO
∆50 mutant is translated less efficiently, leading to its overall decreased toxicity. Surprisingly, our
structural probing results revealed that the zorO ∆50 possesses the same open EAP region as the
zorO ∆28 (Figure 3.6F) even though its translation efficiency is much lower than the zorO ∆28
(Figure 3.6E). Given that the zorO ∆34 is similar to that of the zorO ∆28, the reduced toxicity seen
in zorO ∆50 is likely due to truncation of the sequence from +35 to +50. Therefore, these data
implied that the region between +35 to +50 harbors an additional element that contributes to zorO
translation (see discussion).
The OrzO sRNA causes both translation inhibition and degradation of the zorO mRNA Our
previous study demonstrated that base pairing of the OrzO sRNA to the zorO mRNA triggers
RNase III-dependent degradation (15). Whether this is the only mechanism by which the OrzO
sRNA represses zorO expression is unclear. As mentioned above, the structural probing data
revealed that the OrzO sRNA can base pair with both the zorO full-length and the zorO ∆28
mRNAs at the 3’ end of the EAP region (Figure 3.3C). If the EAP region acts as a standby site,
base pairing by OrzO would prevent the ribosome from preloading onto the mRNA thus inhibiting
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translation of the zorO mRNA. Under this scenario, the OrzO sRNA would still be capable of
repressing zorO even if RNase III is not present. To test this, we co-expressed the orzO sRNA
gene along with either the zorO full-length or the zorO ∆28 gene in a RNase III deletion (∆rnc)
background to determine if OrzO could still restore bacterial growth from ZorO-induced toxicity.
As shown in Figure 3.7A and 3.7B, bacterial growth stasis caused by overexpression of either the
zorO full-length (0.0001% arabinose) or zorO ∆28 (0.00002% arabinose) was rescued by coexpression of orzO. This indicates that the OrzO sRNA can repress ZorO toxin production in the
absence of RNase III, likely through inhibiting zorO mRNA translation.
To directly assess the influence of the OrzO sRNA on zorO mRNA translation, we
examined the in vitro translation efficiency of either zorO full-length or zorO ∆28 mRNA in the
presence or absence of OrzO. The ZorO protein levels for either mRNA were reduced greatly in
the presence of OrzO (Figure 3.7C). These results are concordant with the observed rescue from
cellular toxicity in vivo (Figure 3.7A and 3.7B) and indicate that OrzO can regulate zorO
expression at the translational level. Interestingly, the OrzO sRNA exhibited a more pronounced
inhibitory effect on translation of zorO ∆28 mRNA as compared to zorO full-length mRNA. This
corroborates with our structural probing results that the zorO ∆28 mRNA has a more accessible
EAP region for OrzO sRNA to bind. We also tested if the OrzO sRNA could impact the translation
of zorO ∆82 RBS mRNA. Only a very mild reduction in ZorO protein levels was observed upon
addition of OrzO sRNA (Figure 3.7D), which further supports the idea that an opened RBS would
render the EAP region dispensable. Collectively, these data suggested that the OrzO sRNA
represses ZorO production by affecting both translation and stability of the zorO mRNA.

IV. Discussion
In this study, we show that the 5’ UTR of zorO regulates the production of ZorO toxin from three
major aspects. First, the 5’ UTR affects the stability of the zorO mRNA as almost all zorO
truncation mutants tested exhibited decreased RNA levels as compared to the zorO full-length.
Second, the 5’ UTR modulates the translation of the zorO mRNA through two distinct regions.
One region, EAP, is exposed only upon processing and is a putative ribosome standby site that
likely facilitates ribosome preloading onto the mRNA, thereby promoting zorO translation. The
other region spans from +35 to +50 of zorO and is required for optimal translation of zorO,
although the underlying mechanism remains unclear (see below). Third, the zorO 5’ UTR serves
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as the target site of the antitoxin sRNA OrzO. The OrzO sRNA base pairs to the 3’ of the EAP
region of zorO and inhibits zorO translation, likely by competing with ribosomes for the EAP
region. This base pairing also stimulates zorO degradation in an RNase III-dependent fashion (15),
thereby preventing accumulation of the zorO mRNA.
Optimal translation of zorO requires a standby site The 5’ UTR mediated translational
regulation of ZorO toxin synthesis is reminiscent to that of the TisB toxin of the type I pair tisABistR of E. coli. Without IstR-1 sRNA base pairing, the tisAB mRNA possesses two forms: a fulllength form (+1) and a processed form (+42) (14). The RBS of both forms of tisAB are folded in
stems. Our work revealed that the zorO mRNA also exists in a full-length form and a processed
form (∆28) (15). Structural probing data demonstrated that the RBS is shielded in stems in both
the zorO full-length and the ∆28 mRNAs. The processed tisAB undergoes structural changes at the
5’ UTR as compared to full-length tisAB and opens a standby site that was initially sequestered in
full-length transcript (14). Similar structural rearrangement also occurs in zorO upon processing
of the zorO 5’ UTR, which leads to exposure of a single-stranded region in the zorO ∆28 that spans
from +73 to +102 (the EAP region). Additionally, the processed tisAB exhibited robust translation
whereas the full-length tisAB is translationally inert (14). Our results from the toxicity and in vitro
translation assays also showed that zorO ∆28 has increased translation relative to full-length zorO.
Given these extensive similarities between zorO and tisAB, it is likely that the translation of zorO
follows the standby model and the EAP region serves as a standby site.
Unlike tisAB, both the zorO full-length and the zorO ∆28 forms are translatable (Figure
3.1E). Hence, the putative standby region of zorO can promote translation, but is not required for
translation. As proposed by de Smit et al, a standby site operates by increasing the local
concentration of ribosomes given that the time window during which a folded RBS is transiently
opened is too short to efficiently recruit ribosomes (29). Thus, the effect of a standby site is
dependent on the opening of the closed RBS. Our data comparing the zorO ∆82 versus zorO ∆82
RBS mutant showed that despite the perturbation of the standby site, translation of the toxin
mRNAs were recovered after permanently exposing the RBS. This suggests the standby site is
dispensable when the RBS is exposed. Therefore, although zorO full-length may not harbor an
accessible standby site, transitory opening of the RBS in zorO may provide an opportunity for
translation to occur.
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Potential requirement for ribosome to preload onto a standby site As mentioned above, the
translational regulation of zorO by its 5’ UTR likely follows the standby model as proposed in
tisAB, though the actual lengths of the standby sites vary for each. The features of a standby site
that allow ribosome preloading remain unclear. For normal translation initiation, the 30S subunit
of the ribosome anchors onto the mRNA through base pairing interactions between the 3’ terminus
of 16S rRNA and the RBS of the mRNA. We do not recognize any obvious complementary
sequence in zorO or tisB that could base pair with the 3’ of 16S rRNA

However, it has been

shown that alternative sequence features of the mRNA, other than complementarity to the 16S
rRNA, can permit 30S subunit preloading onto mRNA. Studies by Barendt et al revealed that
translation initiation of non-Shine Dalgarno-led genes exhibit unique preferences on certain
purines or pyrimidines at the 5’ UTR (30,31). We note that both the zorO and the tisB mRNAs
contain a stretch of 5-nt-long sequence (5’ CAACA 3’) at the 3’ end of predicted standby site
where the corresponding antitoxin sRNA targets. Whether this stretch of sequence plays a role in
anchoring the ribosome is currently under investigation.
A more widely accepted feature of a standby site suggests that preloading of the ribosome
onto a standby site is predominantly dependent on the single stranded nature of the site. Using
fluorescence energy transfer experiments on designed mRNAs containing different secondary
structures, Studer et al revealed that a single-stranded region in a structured mRNA allows the
binding to the 30S subunit of the ribosome in a sequence independent manner (32). Another recent
study also suggests that hairpin structures harboring single-stranded surface can function as
standby sites regardless of their sequences (28).
Given that the association affinity between a standby site and the 30S subunit may not be
as strong as that in the translation initiation complex, direct biochemical detection of a bound form
of 30S with the standby site can be challenging. It is noteworthy that the sequence and the structure
requirements of a standby site may not be mutually exclusive. Hence, it is possible that one standby
site can harbor both specific sequence features as well as structure features.
Optimal translation of zorO requires an additional site Along with the EAP standby region, we
identified another region spanning from +35 to +50 that contributes to zorO translation. We could
not resolve the structure of this region due to poor RNase T1 cutting, but our lead(II) digestion
indicated that the +35 to +50 region comprises a stretch of single nucleotides and a stem (Figure
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3.8). A study by Borujeni et al suggested that any single hairpin structure surrounded by distal and
proximal single-stranded binding sites could serve as a standby site and contribute to translation
(28). Hence, perhaps the single-stranded sequences in the +35 to +50 region could also promote
ribosome loading. However, a synthetic sRNA that can base pair with this region failed to rescue
cells from zorO induced toxicity in a ∆rnc strain (data not shown), implying that sRNA pairing to
this region does not interfere with zorO translation. Therefore, it is unlikely that this region serves
as a site for ribosome loading.
Another possibility is that this region may impact the kinetics of RNA unfolding. RNA can
adopt different structures before reaching its native fold (33). The folding process can occur in a
sequential fashion in which the first stable structure formed directs subsequent folding (34). In line
with this, one may imagine that there could be many alternative ways for a structured RNA to
reverse to a “functional” unfolded state. Perhaps the presence of the +35 to +50 region confines
the choices of possible unfolding pathways and streamlines this unfolding process, therefore
allowing a more rapid translation of zorO. Additionally, it has been suggested that the folding of
some RNAs occurs in a cooperative fashion that requires interactions of different portions of the
RNA, as exemplified by the RNase P of B. subtilis (35). This raises the possibility that the +35 to
+50 region may accelerate the folding/unfolding of the zorO RNA but not impact the final structure.
This could explain why lack of this region results in reduced translation efficiency (Figure 3.6E)
although the overall structure was not affected. Additional studies of zorO RNA unfolding could
provide mechanistic insights on how this region affects zorO translation.
Alternative model for zorO translation Another mode of regulation of type I toxins is the
translation coupling model represented by mok-hok (10,36). In this model, translation of the hok
toxin mRNA is dependent on the translation of a leader peptide, Mok, encoded in the long 5’ UTR
of hok. The RBS of mok is sequestered in secondary structure and only exposed upon 3’ processing
of hok (12,13). In zorO, structural alteration is mediated by 5’ processing instead of the 3’
processing seen in hok. Further, no AUG start codon is found within the zorO 5’ UTR. Although
there are several GUG or UUG sequences that may serve as an alternative start codon, no canonical
RBS is detected upstream of these sequences nor are they located within the EAP. Given that the
translation coupling model requires the presence of a leader peptide, it is unlikely that the zorO
mRNA uses this mechanism to initiate its translation.
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Besides ZorO and TisB, 5’ processing has been observed in two other type I toxins in E. coli, ShoB
and DinQ, and appears linked to the translational efficiency of those toxin mRNAs. Specifically,
two forms of shoB transcripts were detected: a full-length form (~320 nts) and a 5’ processed form
(~280 nts) (5), but only the processed form showed measurable β-galactosidase activities when
fused translationally to lacZ (2). Further, dinQ possesses four processed forms yet only one
transcript (+44) was translationally active (37). These observations suggest that optimal translation
of shoB or dinQ requires 5’ processing, likely through de-repressing the inhibitory effects caused
by their respective 5’ UTRs. This raises the possibility that similar to zorO and tisB, the shoB and
dinQ may use standby sites to facilitate translation; furthermore, their respective antitoxins OhsC
and AgrB may act by targeting the standby sites. Surprisingly, the zorO-orzO, tisB-istR, shoBohsC, and dinQ-agrB type I pairs share two distinct features: the toxin is encoded divergently from
the corresponding antitoxin sRNA gene and base pairing occurs distal from the RBS at the toxin
5’ UTR. Indeed, these four type I loci are the only ones identified to date that follow such genetic
arrangement and base pairing pattern. It would be interesting to see whether the shoB-ohsC and
dinQ-agrB pairs employ the standby mechanism to regulate toxin production, and if they do, the
next fascinating question would be: can we predict the regulatory mechanisms of a type I pair
based on its intrinsic genetic arrangement and the base pairing pattern?
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Appendix III: chapter III tables and figures
Table 3.1. Strains and plasmids used in this study.
Name
Escherichia coli EDL933
DJ480
UTK007
UTK011

Relevant genotype or description
Wild type EHEC, O157:H7
MG1655 ΔlacX74 (wild type strain)
DJ480 PCP18-araE
UTK007 Δrnc::kan

Source
D. Friedman
D. Jin, (11)
(12)
(12)

Plasmids
pFA6a-GFP(S65T)-kanMX6
pEF21
pEF21-zorO full-length
pEF21-zorO ∆28
pAZ3
pAZ3-zorO full-length
pAZ3-zorO Δ28
pAZ3-zorO Δ34
pAZ3-zorO Δ50
pAZ3-zorO Δ82
pAZ3-zorO Δ82 RBS
pAZ3-zorO UTR-gfp
pAZ3-Δ28 UTR-gfp
pBR-pLac
pBR-pLac-orzO
pGEM®-3Zf(+)

AmpR; KmR
CmR; PBAD promoter; 10 - 12 copies per cell
CmR
CmR
CmR; PBAD promoter; 15 - 20 copies per cell
CmR
CmR
CmR
CmR
CmR
CmR
CmR
CmR
AmpR; PLlacO promoter
AmpR
AmpR; T7 promoter

(24)
(46)
(12)
This study
(17)
This study
This study
This study
This study
This study
This study
This study
This study
(11)
(12)
Promega

pGEM-T7-zorO full-length
pGEM-T7-zorO ∆50
pGEM-T7-zorO ∆82
pGEM-T7-zorO ∆82 RBS

AmpR
AmpR
AmpR
AmpR

This study
This study
This study
This study
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Table 3.2. Oligonucleotides used in this study
Name

a

Sequencea

Use

EF524

GTTGGTACGAAACGTTGCTCTCCG

Northern analysis of zorO, zorO UTR-gfp and their derivatives

EF1065

CAGTGAGTGAGATTTATAATCGAATTCGTTGGGAG

pAZ3-zorO full-length PCR; pAZ3-zorO UTR-gfp PCR; pGEMT7-zorO full-length PCR

EF1068

ATACTCAAGCTTATTAAAGTCGCAGCACATGCAAC

pAZ3-zorO full-length PCR; pAZ3-zorO Δ28 PCR; pAZ3-zorO
Δ50 PCR; pAZ3-zorO Δ82 PCR; pEF21-zorO ∆28 PCR

EF1141

GGTTGTGCCGGATCGGAATTCTTTTAAGTCCTGGCTGC

pAZ3-zorO Δ28 PCR; pAZ3-Δ28 UTR-gfp PCR

EF1127

GACCAAGAATTCGTCCTGGCTGCCGGACGGGTGGTGCCGC

pAZ3-zorO Δ34 PCR

EF1066

GATAATTAAGCTTGCAGCACATGCAACTTGAAG

pAZ3-zorO Δ34 PCR

EF1170

CAATTTTAAGTCCTGGCTGGAATTCGGGTGGTGCCGCAGGC

pAZ3-zorO Δ50 PCR; pGEM-T7-zorO ∆50 PCR

EF392

GCCCTGGAATTCAGAGCAACGTTTCGTACCAAC

pAZ3-zorO Δ82 PCR; pGEM-T7-zorO ∆82 PCR

EF1290

GTGTAAGGGTAAGGTGCTGGTGTTGCGTTGGTAAATAAGGAGA
GCGGATGGACACGCTGAC

pAZ3-zorO ∆82 RBS PCR; pGEM-T7-zorO ∆82 RBS PCR

EF1291

GTCAGCGTGTCCATCCGCTCTCCTTATTTACCAACGCAACACCA
GCACCTTACCCTTACAC

pAZ3-zorO ∆82 RBS PCR; pGEM-T7-zorO ∆82 RBS PCR

EF1181

GAAAAGTTCTTCTCCTTTCATCCGCTCTCCTTATTAAGG

pAZ3-zorO UTR-gfp PCR

EF1182

CCTTAATAAGGAGAGCGGATGAAAGGAGAAGAACTTTTC

pAZ3-zorO UTR-gfp PCR

EF1183

GAAATTCGCTTATTTAGAAGCTTCGCGCCCTATTTGTATAG

pAZ3-zorO UTR-gfp PCR

EF1328

GGTTGTGCCGGATCGCTGCAGTTTTAAGTCCTGGCTGC

pEF21-zorO ∆28 PCR

EF1343

GAGTATAGCTCCCGGGAAGGGGGAAACGGTATTC

pGEM-T7 zorO full-length PCR; pGEM-T7-zorO ∆50 PCR;
pGEM-T7-zorO ∆82 PCR; T7-zorO ∆28 PCR

EF1408

GAGTCTGCAGAAGCTTTAATACGACTCACTATAGGGCGAATTC
TTTTAAGTCCTGGCTGCCGGACGGGTG

T7-zorO ∆28 PCR

5' - 3', restriction sites underlined, nucleotides altered via site directed mutagenesis in red.
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Figure 3.1. The 5’ processed form of zorO (zorO ∆28) shows enhanced translation. (A) Sequence
details of the zorO gene. Region of base pairing is shaded in grey. The predicted -35 and -10
promoter elements, the start codon, and the stop codon of zorO are indicated in bold. Transcription
start site of the zorO full-length is highlighted in red. Transcription start site of each zorO
truncation mutant is highlighted in color with the mutant name listed in the same color. The EAP
region is labeled in red. The RBS of zorO is highlighted in yellow and the region base pairing with
the RBS in the stem structure is underlined. (B) E. coli strain UTK007 harboring pAZ3-zorO was
grown to mid-log, split, and arabinose added to the final concentration indicated by the arrow.
Shown are the averages ± standard deviations for three independent cultures. (C) UTK007
harboring pAZ3-zorO or pAZ3-zorO ∆28 was grown in LB supplemented with 0.2% glucose to
exponential phase, washed, and arabinose was added as indicated by the arrow. Shown are the
mean values ± standard deviations for three independent cultures. (D) Total RNA was isolated
from E. coli MG1655 harboring pAZ3-zorO or pAZ3-zorO ∆28 at the indicated times following
the addition of 0.0001% arabinose to exponentially growing cultures (OD600 = 0.2 - 0.3). Shown
is a representative of three independent northern blots. (E) In vitro translation assays with [35S]Met were performed as described in the Material and Methods with 0.25 µM of zorO full-length
or zorO ∆28 mRNAs. No RNA was added to the negative control. Quantification of band
intensities were determined using ImageJ (38). The intensity of the band representing the zorO
full-length was set to 100% translational efficiency.
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Figure 3.1. (continued)
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Figure 3.2. The 5’ UTR-mediated translation effects can be transferred to gfp. (A) Shown are
histograms comparing fluorescence intensity of GFP in pAZ3- zorO UTR-gfp or pAZ3-∆28 UTRgfp without arabinose induction. Black line indicates 0 min post induction, red indicates 30 min
post induction, and blue indicates 60 min post induction. Shown is a representative histogram of
three independent experiments. (B) Shown are histograms comparing fluorescence intensity of
GFP from cells harboring either pAZ3-zorO UTR-gfp or pAZ3-∆28 UTR-gfp after 0.2% arabinose
induction. The black line indicates 0 min post induction, red indicates 30 min post induction, and
blue indicates 60 min post induction. Shown is the representative histogram of three independent
experiments. (C) Fold difference in gfp expression as determined by geometric mean fluorescence
and normalized to uninduced controls. Gray bars indicate pAZ3-zorO UTR-gfp and black bars
indicate pAZ3-∆28 UTR-gfp. Shown are the mean values ± standard deviations for three
independent experiments.

114

Figure 3.2. (continued)
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Figure 3.3. The 5’ processing of zorO does not alter RBS structure, but exposes a single-stranded
region (EAP region). (A) The RBS of both zorO full-length and zorO ∆28 are in a stem structure.
5′-end-labeled zorO full-length or zorO ∆28 RNA was subjected to RNase T1 and lead(II) acetate
cleavage as described in the Material and Methods. C, control RNA; Ladder/T1, RNase T1 ladder
of indicated RNA; Ladder/OH, Alkaline ladder; Reaction/T1, RNase T1 digestion under
denaturing condition; and Reaction/Lead, Lead(II) acetate digestion under denaturing condition.
The position of selected cleaved G residues is given at the left of each T1 ladder. Yellow boxes
indicate the RBS region of each zorO transcript. (B) In vitro structure probing of 3’-end-labeled
zorO and its derivatives. 3′-end-labeled zorO full-length, zorO ∆28, zorO ∆50, or zorO ∆82 RNA
(1.67 µM) was subjected to RNase T1 and lead(II) acetate cleavage as outlined in Figure 3A. The
position of selected cleaved G residues is given at the left of the T1 ladder. Yellow boxes indicate
the corresponding RBS of zorO full-length, zorO ∆28, zorO ∆50, and zorO ∆82. (C) In vitro
structure probing was conducted as in (A). The position of selected cleaved G residues is given at
the left of each T1 ladder. Red boxes indicate the corresponding EAP region (+73 to +102 from
zorO full-length transcription start site) of zorO full-length and zorO ∆28. (D) The OrzO sRNA
can base pair with both zorO full-length and zorO ∆28 at the 3’ end of EAP region. Lead(II) acetate
structure probing was conducted as in (A) with addition of 0 (-), 0.25 µM (+), and 0.5 µM (++)
unlabeled OrzO sRNA. Red boxes indicate the corresponding EAP region of the zorO full-length
and zorO ∆28. Black bars indicate the region protected by OrzO binding. Base pairing between
zorO and OrzO is shown on the bottom.
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Figure 3.3. (continued)
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Figure 3.3. (continued)
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Figure 3.3. (continued)
119

Figure 3.3. (continued)
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Figure 3.4. Disruption of the EAP region of zorO leads to decreased translation. (A) Toxicity
assay was performed as in Figure 3.1A with either zorO full-length or zorO ∆82 induced by 0.0001%
arabinose. Shown are the mean values ± standard deviations for three independent cultures. (B).
Toxicity assay was performed as in Figure 3.1A with either zorO full-length or zorO ∆82 induced
by 0 (uninduced control) or 0.2% arabinose. Shown are the mean values ± standard deviations for
three independent cultures. (C) Expression of zorO ∆82 induced by 0.2% arabinose is similar to
or higher than zorO full-length induced by 0.0001% arabinose. Total RNA was isolated from E.
coli MG1655 harboring pAZ3-zorO or pAZ3-zorO ∆82 at 0, 5, 15, 30, and 60 min following the
addition of either 0.0001% (to induce zorO full-length) or 0.2% (to induce zorO ∆82) arabinose to
exponentially growing cultures. Shown is a representative of three independent northern blots. (D)
In vitro translation assays with [35S]-Met were performed as described in the Material and Methods
with 0.25 µM of zorO full-length, zorO ∆82, or zorO ∆82 RBS mRNAs. No mRNA was added to
the negative control. Quantification of band intensities were determined using ImageJ (38). The
intensity of the band representing the zorO full-length was set to 100% translational efficiency.
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Figure 3.4. (continued)
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Figure 3.5. Exposing the RBS rescues the translational defect of zorO ∆82. (A) Toxicity assay
was performed as in Figure 3.1A with either zorO full-length or zorO ∆82 RBS by either 0.0001%
or 0.00001% arabinose. Shown are the mean values ± standard deviations for three independent
cultures. (B) Total RNA was isolated from E. coli MG1655 harboring pAZ3-zorO, pAZ3-zorO
∆82, or pAZ3-zorO ∆82 RBS at 0, 5, 15, 30, and 60 min following the addition of 0.0001%
arabinose to exponentially growing cultures. Shown is a representative of three independent
northern blots.
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Figure 3.6. The 5’ UTR contains an additional region that impacts zorO translation. (A). Toxicity
assay was performed as in Figure 3.1B with either zorO full-length or zorO ∆34 induced by
0.00001% arabinose. Shown are the mean values ± standard deviations for three independent
cultures. (B). Total RNA was isolated from E. coli MG1655 harboring pAZ3-zorO full-length or
pAZ3-zorO ∆34 at 0, 5, 15, 30, and 60 min following the addition of 0.0001% arabinose to
exponentially growing cultures. Shown is a representative of three independent northern blots. (C)
Toxicity assay was performed as in Figure 3.1A with either zorO full-length or zorO ∆50 induced
by 0.0001% arabinose. Shown are the mean values ± standard deviations for three independent
cultures. (D) Total RNA was isolated from E. coli MG1655 harboring pAZ3-zorO or pAZ3-zorO
∆50 at 0, 5, 15, 30, and 60 min following the addition of 0.0001% arabinose to exponentially
growing cultures. Shown is a representative of three independent northern blots. (E) In vitro
translation assays with [35S]-Met were performed as described in the Material and Methods with
0.25 µM of zorO full-length, zorO ∆28, or zorO ∆50 mRNAs. No mRNA was added to the negative
control. Quantification of band intensities were determined using ImageJ (38). The intensity of the
band representing the zorO full-length was set to 100% translational efficiency. (F) In vitro
structure probing was conducted as in Figure 3.3A. Red boxes indicate the corresponding EAP
region of zorO ∆28 and zorO ∆50.

124

Figure 3.6. (continued)
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Figure 3.6. (continued)
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Figure 3.7. OrzO sRNA inhibits translation of zorO transcripts. (A) E. coli strain UTK011
carrying pBR-plac-orzO and pEF21-zorO was induced as indicated with arabinose (0.0001%)
and/or IPTG (1mM). Shown are the mean values ± standard deviations for three independent
cultures. (B) Rescue experiment was performed as in (A) with zorO ∆28 expressed induced by
0.00002% arabinose. Shown are the mean values ± standard deviations for three independent
cultures. (C) In vitro translation assays with [35S]-Met were performed as described in the Material
and Methods with 0.1 µM of zorO full-length or zorO ∆28 mRNAs. 5 µM of OrzO RNA were
added as indicated. Quantification of band intensities were determined using ImageJ (38). The
intensity of the band representing the zorO full-length without the addition of OrzO was set to 100%
translational efficiency. (D) In vitro translation assays with [35S]-Met were performed as described
in the Material and Methods with 0.1 µM of zorO full-length, zorO ∆82, or zorO ∆82 RBS mRNAs.
5 µM of OrzO RNA were added as indicated. Quantification of band intensities were determined
using ImageJ (38). The intensity of the band representing the zorO full-length without the addition
of OrzO was set to 100% translational efficiency.
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Figure 3.8. The +35 to +50 region in zorO full-length and zorO ∆28. In vitro structure probing
was conducted as in Figure 3.3 A. Purple bars indicate the corresponding +35 to +50 region of
zorO full-length and zorO ∆50.
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Figure 3.8. (continued)
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CHAPTER IV

Characterization of the type I toxin ZorO of E. coli O157:H7
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Publication note
This chapter is in preparation for submission. The tentative title is:
Jia Wen, Huston T. Heatherly, John R. Harp, and Elizabeth M. Fozo. Characterization of the type
I toxin ZorO of E. coli O157:H7 [In preparation].
My contribution to this chapter was mutant constructions, toxicity assays, the literature
review, and the writing. John R. Harp assisted in generating data presented in Figure 4.2, where
he performed the flow cytometry analyses. Huston T. Heatherly assisted in generating data
presented in Figure 4.4, where he performed the toxicity assays with pAZ3-zorO E16R, pAZ3zorO R23E, and pAZ3-zorO E16R/R23E. I performed all other experiments.
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Abstract
Most type I toxins are small hydrophobic proteins that possess a putative transmembrane domain.
We previously showed that the zorO-orzO gene pair in Escherichia coli O157:H7 is a true type I
toxin-antitoxin locus, with zorO encoding the toxic protein and orzO encoding the antitoxin sRNA.
Overproduction of zorO is toxic and can cause cell growth stasis or cell death. This toxic phenotype
is solely due to the function of the ZorO protein and not due to the zorO mRNA. ZorO
overproduction leads to rapid membrane depolarization, suggesting that it targets the inner
membrane. Six charged amino acids are found in the ZorO sequence, arranged in an alternating
charge pattern. Two residues, glutamic acid at the 16th position (E16) and arginine at the 23rd
position (R23), are predicted to reside in the putative transmembrane domain of ZorO. Mutational
studies show that replacement of the E16 and/or R23 with amino acids carrying no charge or
opposite charge impairs the toxicity of ZorO. However, the reduction in toxicity varies between
different mutants, indicative of roles of both the charge and the amino acid position in determining
ZorO toxicity.
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I. Introduction
A bacterial type I toxin-antitoxin (TA) system is composed of a toxic protein whose
overproduction causes cell growth stasis or cell death and an antitoxin small RNA (sRNA) that
can inhibit production of the toxin by base pairing with its mRNA. The first described type I system,
hok-sok, is located on the R1 plasmid of Escherichia coli where it functions to maintain the plasmid
in a bacterial population through a post-segregational killing mechanism (1). With increasing
numbers of bacterial genomes sequenced, homologs of hok-sok and novel type I loci have since
been identified in bacterial chromosomes.
Most identified type I toxins share common biochemical features. They are small
hydrophobic proteins (< 60 amino acids) with a single putative transmembrane domain and are
hypothesized to function at the cytoplasmic membrane (2). Indeed, overproduction studies have
confirmed that some type I toxins localize in the inner membrane and disrupt membrane integrity,
as was verified for a Hok homolog (3). Overexpression of the hok gene in E. coli caused membrane
damage and “ghost cells” were clearly visible (1). Similarly, overproduction of the type I toxin
ShoB or IbsC led to rapid membrane depolarization and an immediate change in membrane
potential shortly after induction (4). The TisB toxin also localized in the inner membrane of E. coli
and its overproduction dramatically reduced intracellular ATP concentration (5). In vitro studies
further revealed that the TisB proteins form narrow pores in a planar lipid bilayer causing
membrane depolarization (6). Such membrane damage was suggested to reduce the proton motive
force and impair ATP synthesis, thereby leading to a decline in the overall cellular energy.
Despite the detrimental effects caused by type I toxins, it is believed that bacteria employ
these toxins to reduce both their metabolic and growth rates as means to increase stress tolerance
and promote recovery. It has been reported that when challenged with the DNA-damaging
antibiotic ciprofloxacin, the type I toxin TisB induces persister formation of E. coli cells by
shutting down cellular metabolism (7). Similarly, the chromosomally-encoded hok homolog
known as hokB is transcribed in E. coli in response to nutrient starvation, leading to dormancy (8).
Aside from their roles in stress response, many type I toxins can provide bacteria fitness advantages
in their natural habitats [reviewed in (9,10)]. For instance, deletion of either the type I toxin gene
hok, ldr, or tisB was shown to reduce the survival rate of the intracellular bacterial pathogen
Salmonella enterica serovar Typhimurium inside eukaryotic cells (11).
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Our previous studies demonstrated that the zorO-orzO gene pair in the chromosome of E.
coli O157:H7 (EHEC) is a true type I TA locus, with zorO encoding the toxin and orzO encoding
the antitoxin sRNA (12). The ZorO toxin is 29-amino-acid in size and possesses one potential
transmembrane domain. This suggests that the ZorO protein may employ a similar strategy as seen
with TisB to disrupt the membrane (6). Surprisingly, 20% of the ZorO sequence is made of charged
amino acids. Charged amino acids are usually less commonly found in the transmembrane segment
of a membrane protein (13), and in many cases they are essential for the function of the membranebound protein. For example, in E. coli, a single, membrane-embedded, negatively charged amino
acid (E26) determines the substrate specificity of the multidrug resistance protein MdfA (14).
Further, charged residues have been reported to promote protein-protein interactions, as
exemplified by the ionic interactions between the amphiphilic helix domain and the densely
charged region of the TatA protein (15). Moreover, the positively charged residue R72 within the
transmembrane segment one of the YidC2 protein is essential for proper insertion of YidC
dependent membrane proteins in Bacillus subtilis (16). In this study, we confirm that
overproduction of the ZorO toxin causes membrane damage and identify two charged residues that
appear to be critical for the function of ZorO. The putative mode of action of ZorO within the cell
membrane is also discussed.

II. Material and methods
Bacteria strains and plasmids All bacterial strains and plasmids used in this study are listed in
Table 4.1. The sequences of all oligonucleotides are listed in Table 4.2.
Growth conditions E. coli strains were grown at 37°C in Luria–Bertani (LB) medium with
shaking. Chloramphenicol was added at a final concentration of 25 µg/ml when necessary.
Arabinose was added at a final concentration between 0.0001% and 0.2% as indicated.
Plasmid construction Mutations of individual nucleotides were performed through site-directed
mutagenesis as described previously (17).
Overproduction of ZorO toxin ZorO toxicity assays were performed as described previously
(12). Briefly, the pAZ3 plasmid harboring the zorO wild type or mutant gene under the PBAD
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arabinose inducible promoter was transformed into E. coli strain UTK007 through electroporation
(18). The resulting transformants were grown overnight and then diluted to an OD600 of 0.01. When
the OD600 reached ≈ 0.3, the cultures were split and arabinose was added to half the culture as
indicated to overexpress the gene. OD600 was recorded every 30 min. Shown are averages ±
standard deviations for a minimum of three independent experiments.
Flow cytometry analysis E. coli cells carrying the pAZ3-zorO wild type plasmid were grown as
previously indicated to an OD600 ≈ 0.3 and split into two cultures. One culture was induced with
0.2% arabinose and the other served as the control (time 0). At 0, 5, 15, 30, or 60 min postinduction, 50 µl aliquots were taken, flooded with 4 ml of 1X PBS and centrifuged. Cell pellets
were resuspended in 1 ml of 1X phosphate-buffered saline (PBS) and stained with 10 µg/ml
DiBAC4(3) [bis-(1,3-dibarbituric acid)-trimethine oxanol] (Life Technologies). Cells were
incubated at room temperature for 30 min in the dark, washed with 4 ml of 1X PBS extensively
twice, and then resuspended in 0.5 ml 1X PBS for cells harvested at 0, 5, or 15 min, or in 1 ml 1X
PBS for cells harvested at 30 and 60 min, and analyzed by flow cytometry in a LSR II flow
cytometer (Becton Dickinson) with a 488-nm laser. Samples were run at an event rate of 3,000
events per second. DiBAC4(3) fluorescence was collected in the fluorescein isothiocyanate (FITC)
channel. Differences in induction versus control were obtained using geometric mean fluorescence
for n = 3.

III. Results
ZorO confers toxicity as a protein and not as a small RNA In addition to their protein function,
the mRNAs of certain small proteins possess a regulatory role (19). For example, the 43-aminoacid SgrT protein of E. coli is produced under glucose-phosphate stress and inhibits glucose
transport by modulating the activity of the glucose transporter PtsG. Moreover, the RNA that
encodes SgrT, known as the SgrS sRNA, can base pair and destabilize the mRNA of the same
glucose transporter (20,21). Hence, the response towards glucose-phosphate stress is attributed to
both the effects of the SgrT protein and that of the SgrS sRNA. With this in mind, we first wanted
to know whether the zorO mRNA plays a role in the toxic phenotype resulting from zorO
overexpression.
135

To test this, we constructed a zorO AAG mutant under an arabinose inducible PBAD
promoter in which the start codon of zorO is mutated to AAG to disrupt translation. If the toxic
phenotype seen in zorO overexpression is dependent upon its function as a protein, we would
expect to see a loss of the phenotype. Indeed, as shown in Figure 4.1, the zorO AAG mutant failed
to confer cell growth stasis under saturating levels of the inducing agent arabinose (0.2%
arabinose). This suggests that the toxicity conferred by zorO relies entirely on the biochemical
function of the ZorO protein.
Overproduction of ZorO causes membrane depolarization Since the ZorO protein is very
hydrophobic and is predicted to contain a transmembrane domain, we examined whether it can
cause cell membrane damage similar to the overproduction of type I toxins ShoB and IbsC (4). E.
coli harboring pAZ3-zorO wild type was induced with 0.2% arabinose for ZorO overproduction;
cells were subsequently incubated with DiBAC4(3) to monitor membrane depolarization (22). As
shown in Figure 4.2A and 4.2B, overproduction of ZorO caused significant membrane damage
whereas there was no damage in the control cells. More specifically, within 5 min after induction,
57% of the cells overproducing ZorO were positive for membrane depolarization; this increased
to over 97% of the population within 15 min of induction. Along with membrane depolarization,
we also noted a dramatic loss in viable cells within 15 min post induction (data shown in Chapter
3). Moreover, when reduced amounts of arabinose was used for induction (0.0001%), the kinetics
of membrane depolarization were slower (data not shown), but still resulted in significant
membrane depolarization over time. These data suggest that the ZorO toxin targets the cell
membrane, leading to membrane depolarization and eventual cell death, when expressed at high
enough levels.
Specific charged amino acids are important for ZorO toxicity When examining the protein
sequence of ZorO, we noted that its predicted transmembrane domain possesses two charged
amino acids: glutamic acid (E) at the 16th position and arginine (R) at the 23rd position (Table 4.3).
As mentioned above, charged residues in membrane associated proteins are shown to be essential
for their functions. To test if either E16 or R23 in ZorO contributed to its function, we first
substituted these charged residues with neutral amino acids and evaluated the toxicity of the
resultant mutants. As shown in Figure 4.3A, replacement of the negatively charged glutamic acid
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with glutamine (Q) at position 16 caused a mild reduction in ZorO toxicity. When induced by
0.0001% arabinose, only the zorO wild type, but not the zorO E16Q mutant, caused complete cell
stasis. However, when induced with 0.0005% arabinose, the zorO E16Q exhibited the same cell
growth repression as the wild type zorO. This suggested that the ZorO E16Q was still toxic, but
not as potent as ZorO wild type. On the contrary, substituting the positively charged arginine at
the 23rd position of ZorO with a leucine (L) completely abolished the toxicity of ZorO (Figure
4.3B). The ZorO R23L mutant failed to confer cell growth stasis even if it was induced by the
maximum amount of arabinose (0.2% final concentration). In addition, the zorO E16Q/R23L
double mutant showed the same nontoxic phenotype as the zorO R23L mutant (Figure 4.3C).
Taken together, neutralization of the charge at the 16th or the 23rd position of ZorO impairs the
toxicity of ZorO.
We then tested if the specific positive or negative charges are required at the
aforementioned positions to maintain full toxicity of ZorO. We constructed additional mutants in
which the glutamic acid at the 16th position and/or the arginine at the 23rd position were substituted
with amino acids with the opposite charge. The zorO E16R, zorO R23E, and zorO E16R/R23E,
were then subjected to toxicity assays. As shown in Figure 4.4, all three mutants showed a
moderate reduction of the toxicity of ZorO and could only confer full growth stasis when the
concentration of the inducing agent arabinose was 0.005% or above 0.005%. These data suggest
that the nature of the charge at these two positions also plays a role in determining ZorO toxicity.

IV. Discussion
In this study, we have begun to address the key features of ZorO that are critical for toxicity. Upon
overproduction, ZorO causes rapid membrane depolarization, resulting in cell growth stasis or cell
death. Such toxicity is solely dependent on the biochemical function of the ZorO protein as a zorO
mutant without a functional start codon failed to confer cell stasis. Additionally, we also
investigated the role of the two charged amino acids, glutamic acid at the 16th position and arginine
at the 23rd position, and showed that disruption of the native charge at these positions impairs ZorO
toxicity.
Our data clearly showed that the ZorO toxin targets the cell membrane. However, it is still
unclear how exactly the toxin affects the membrane. It has been suggested that the type I toxin
TisB disrupts membrane integrity by dimerizing and forming pores (15). Walther et al proposed
137

that the opposite charged amino acids on two monomers of the TisB protein form salt bridges,
allowing the TisB monomers to assemble into an antiparallel dimer in a “charge zipper” fashion.
Interestingly, we noted that similar to TisB, the ZorO protein contains six charged amino acids and
those charged amino acids are arranged in an alternating pattern. Additionally, two charged amino
acids, glutamic acid at the 16th position and arginine at the 23rd position, are localized on the same
side of the α-helix as predicted by the helical wheel projection program (data not shown). Such
positioning may allow for potential electrostatic interactions with a nearby protein containing
opposite charges. Therefore, it is possible that ZorO dimerizes in the membrane and forms “charge
zippers” as predicted for TisB (15) and that disruption of those amino acid charges would impair
the toxicity of ZorO.
In agreement with this, our mutational studies demonstrated that ZorO E16Q, ZorO R23L,
ZorO E16Q/R23L, ZorO E16R, and ZorO R23E all have decreased toxicity. These results
confirmed the importance of the appropriate charges at these positions for ZorO function. However,
we found that the extent of toxicity reduction varied in response to the residue mutated. Having a
charge at the 23rd position seems more essential than at the 16th position as R23L ZorO is nontoxic but E16Q still maintained toxicity, albeit reduced compared to the wild type ZorO. At this
point, we are unclear why the 23rd position is more important. Additional mutational studies and
modeling/simulations would provide more insights into the connection between the location of the
charges and the impact on ZorO toxicity.
To our surprise, the ZorO E16R/R23E mutant also exhibited reduced toxicity. Since the
charges at the 16th and the 23rd positions are both reversed in this mutant, the electrostatic
interactions could still be maintained if ZorO forms antiparallel dimers. However, given that the
charged amino acids in ZorO are not evenly spaced, the antiparallel charged zipper formed by two
ZorO proteins may not be perfectly aligned. Therefore, reversing the charge may affect the overall
positioning of the two ZorO monomers and lead to inefficient dimerization. Topology analysis of
ZorO can shed light on the protein-protein interactions of both ZorO WT and/or ZorO mutants.
When we predicted the topology of the ZorO protein using different programs, we obtained
contradictory results (Table 4.3). Some small proteins of E. coli possess dual topology, which
could result in ambiguous topology predictions, as exemplified by the YnhF, YoaK, and YohP
proteins (23). Hence, it is possible that the ZorO protein may also exhibit dual topology, which
could permit the assembly of antiparallel dimers. Fusions of ZorO with GFP or PhoA would aid
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in the elucidation of its topology as GFP only functions in the cytoplasm whereas PhoA functions
only in the periplasmic space. Ongoing studies will focus on using structural modeling and
biochemical approaches to characterize the topology and in vivo activity of ZorO protein.

139

References
1.

Gerdes, K., Rasmussen, P.B. and Molin, S. (1986) Unique type of plasmid maintenance
function: postsegregational killing of plasmid-free cells. Proc Natl Acad Sci U S A, 83,
3116-3120.

2.

Fozo, E.M., Hemm, M.R. and Storz, G. (2008) Small toxic proteins and the antisense RNAs
that repress them. Microbiol Mol Biol Rev, 72, 579-589.

3.

Poulsen, L.K., Refn, A., Molin, S. and Andersson, P. (1991) Topographic analysis of the
toxic Gef protein from Escherichia coli. Mol Microbiol, 5, 1627-1637.

4.

Fozo, E.M., Kawano, M., Fontaine, F., Kaya, Y., Mendieta, K.S., Jones, K.L., Ocampo,
A., Rudd, K.E. and Storz, G. (2008) Repression of small toxic protein synthesis by the Sib
and OhsC small RNAs. Mol Microbiol, 70, 1076-1093.

5.

Unoson, C. and Wagner, E.G. (2008) A small SOS-induced toxin is targeted against the
inner membrane in Escherichia coli. Mol Microbiol, 70, 258-270.

6.

Gurnev, P.A., Ortenberg, R., Dorr, T., Lewis, K. and Bezrukov, S.M. (2012) Persisterpromoting bacterial toxin TisB produces anion-selective pores in planar lipid bilayers.
FEBS Lett, 586, 2529-2534.

7.

Dorr, T., Vulic, M. and Lewis, K. (2010) Ciprofloxacin causes persister formation by
inducing the TisB toxin in Escherichia coli. PLoS Biol, 8, e1000317.

8.

Verstraeten, N., Knapen, W.J., Kint, C.I., Liebens, V., Van den Bergh, B., Dewachter, L.,
Michiels, J.E., Fu, Q., David, C.C., Fierro, A.C. et al. (2015) Obg and membrane
depolarization are part of a microbial bet-hedging strategy that leads to antibiotic tolerance.
Mol Cell, 59, 9-21.

9.

Yamaguchi, Y., Park, J.H. and Inouye, M. (2011) Toxin-antitoxin systems in bacteria and
archaea. Annu Rev Genet, 45, 61-79.

10.

Brielle, R., Pinel-Marie, M.L. and Felden, B. (2016) Linking bacterial type I toxins with
their actions. Curr Opin Microbiol, 30, 114-121.

11.

Lobato-Marquez, D., Moreno-Cordoba, I., Figueroa, V., Diaz-Orejas, R. and Garcia-del
Portillo, F. (2015) Distinct type I and type II toxin-antitoxin modules control Salmonella
lifestyle inside eukaryotic cells. Sci Rep, 5, 9374.

12.

Wen, J., Won, D. and Fozo, E.M. (2014) The ZorO-OrzO type I toxin-antitoxin locus:
repression by the OrzO antitoxin. Nucleic Acids Res, 42, 1930-1946.
140

13.

Ulmschneider, M.B. and Sansom, M.S. (2001) Amino acid distributions in integral
membrane protein structures. Biochim Biophys Acta, 1512, 1-14.

14.

Edgar, R. and Bibi, E. (1999) A single membrane-embedded negative charge is critical for
recognizing positively charged drugs by the Escherichia coli multidrug resistance protein
MdfA. EMBO J, 18, 822-832.

15.

Walther, T.H., Gottselig, C., Grage, S.L., Wolf, M., Vargiu, A.V., Klein, M.J., Vollmer,
S., Prock, S., Hartmann, M., Afonin, S. et al. (2013) Folding and self-assembly of the TatA
translocation pore based on a charge zipper mechanism. Cell, 152, 316-326.

16.

Chen, Y., Soman, R., Shanmugam, S.K., Kuhn, A. and Dalbey, R.E. (2014) The role of the
strictly conserved positively charged residue differs among the Gram-positive, Gramnegative, and chloroplast YidC homologs. J Biol Chem, 289, 35656-35667.

17.

Kunkel, T.A. (1985) Rapid and efficient site-specific mutagenesis without phenotypic
selection. Proc Natl Acad Sci U S A, 82, 488-492.

18.

Guzman, L.M., Belin, D., Carson, M.J. and Beckwith, J. (1995) Tight regulation,
modulation, and high-level expression by vectors containing the arabinose PBAD promoter.
J Bacteriol, 177, 4121-4130.

19.

Ulveling, D., Francastel, C. and Hube, F. (2011) When one is better than two: RNA with
dual functions. Biochimie, 93, 633-644.

20.

Vanderpool, C.K. and Gottesman, S. (2004) Involvement of a novel transcriptional
activator

and

small

RNA

in

post-transcriptional

regulation

of

the

glucose

phosphoenolpyruvate phosphotransferase system. Mol Microbiol, 54, 1076-1089.
21.

Wadler, C.S. and Vanderpool, C.K. (2007) A dual function for a bacterial small RNA: SgrS
performs base pairing-dependent regulation and encodes a functional polypeptide. Proc
Natl Acad Sci U S A, 104, 20454-20459.

22.

Wickens, H.J., Pinney, R.J., Mason, D.J. and Gant, V.A. (2000) Flow cytometric
investigation of filamentation, membrane patency, and membrane potential in Escherichia
coli following ciprofloxacin exposure. Antimicrob Agents Chemother, 44, 682-687.

23.

Fontaine, F., Fuchs, R.T. and Storz, G. (2011) Membrane localization of small proteins in
Escherichia coli. J Biol Chem, 286, 32464-32474.

24.

Kawano, M., Aravind, L. and Storz, G. (2007) An antisense RNA controls synthesis of an
SOS-induced toxin evolved from an antitoxin. Mol Microbiol, 64, 738-754.
141

Appendix IV: chapter IV tables and figures
Table 4.1. Strains and plasmids used in this study
Name
UTK007

Relevant genotype or description
DJ480 PCP18-araE

Source
(12)

Plasmids
pAZ3
pAZ3-zorO wild type
pAZ3-zorO AAG
pAZ3-zorO E16Q
pAZ3-zorO R23L
pAZ3-zorO E16Q/R23L
pAZ3-zorO E16R
pAZ3-zorO R23E
pAZ3-zorO E16R/R23E

CmR; PBAD promoter
CmR
CmR
CmR
CmR
CmR
CmR
CmR
CmR

(24)
This study
This study
This study
This study
This study
This study
This study
This study
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Table 4.2. Oligonucleotides used in this study
Name
EF1184
EF1185
EF1186
EF1187
EF1188
EF1189
EF1215
EF1216
EF1217
EF1218
EF1219
EF1220
EF1325
EF1326
a

Sequencea
GCTCATTGCCGTACTGCAGTTATTAGTGGCTCTG
CAGAGCCACTAATAACTGCAGTACGGCAATGAGC
GTTATTAGTGGCTCTGTTACTGTTGATTGATTTGTTGAAG
CTTCAACAAATCAATCAACAGTAACAGAGCCACTAATAAC
CATTGCCGTACTGCAGTTATTAGTGGCTCTGTTACTGTTGATTG
CAATCAACAGTAACAGAGCCACTAATAACTGCAGTACGGCAATG
CGTGCTCATTGCCGTACTGCGGTTATTAGTGGCTCTGTTACG
CGTAACAGAGCCACTAATAACCGCAGTACGGCAATGAGCACG
GAGTTATTAGTGGCTCTGTTAGAGTTGATTGATTTGTTGAAGTAAC
GTTACTTCAACAAATCAATCAACTCTAACAGAGCCACTAATAACTC
CATTGCCGTACTGCGGTTATTAGTGGCTCTGTTAGAGTTGATTGATTTG
CAAATCAATCAACTCTAACAGAGCCACTAATAACCGCAGTACGGCAATG
GCTCCTTAATAAGGAGAGCGGAAGGACACGCTGACACAAAAGTTAAC
GTTAACTTTTGTGTCAGCGTGTCCTTCCGCTCTCCTTATTAAGGAGC

Use
pAZ3-zorO E16Q PCR forward
pAZ3-zorO E16Q PCR reverse
pAZ3-zorO R23L PCR forward
pAZ3-zorO R23L PCR reverse
pAZ3-zorO E16Q/R23L PCR forward
pAZ3-zorO E16Q/R23L PCR reverse
pAZ3-zorO E16R PCR forward
pAZ3-zorO E16R PCR reverse
pAZ3-zorO R23E PCR forward
pAZ3-zorO R23E PCR reverse
pAZ3-zorO E16R/R23E PCR forward
pAZ3-zorO E16R/R23E PCR reverse
pAZ3-zorO AAG PCR forward
pAZ3-zorO AAG PCR reverse

5' - 3', restriction sites underlined, nucleotides altered via site directed mutagenesis in red.
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Table 4.3. Topology predictions of the ZorO toxin

a

Software

Predicted transmembrane domaina

HMMTOP
Memsat
Octopus
Philius
Phobius
Pro
Prodiv
Scampi

LTQKLTVLIAVLELLVALLRLIDLL
LTQKLTVLIAVLELLVALLRLI
LTQKLTVLIAVLELLVALLRLIDLL
LTQKLTVLIAVLELLVALLRLIDL
QKLTVLIAVLELLVALLRLI
LTQKLTVLIAVLELLVALLRLI
LTQKLTVLIAVLELLVALLRLI
LTVLIAVLELLVALLRLIDL

Predicted
orientation
Nout
Nout
Nin
Nout
Nout
Nout
Nout
Nin

ScampiMsa
TMHMM
CCTOP

LTVLIAVLELLVALLRLIDL
KLTVLIAVLELLVALLRLI
LTVLIAVLELLVALLRLID

Nin
Nin
Nout

The full-length ZorO toxin sequence is “MDTLTQKLTVLIAVLELLVALLRLIDLLK”.

Positively charged amino acids are shown in red; negatively charged amino acids are shown in
blue.
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Figure 4.1. Toxicity caused by zorO overexpression is due to ZorO protein activity. E. coli
strain UTK007 harboring pAZ3-zorO wild type or pAZ3-zorO AAG was grown to mid-log, and
arabinose was added to a final concentration of 0.2%. Shown are the averages ± standard
deviations for three independent cultures.
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Figure 4.2. Overexpression of zorO leads to rapid membrane depolarization. Cells containing
the pAZ3-zorO wild type plasmid were grown to an approximate OD600 = 0.3 and split into two
cultures. One culture was left uninduced (A) and the other was induced with 0.2% arabinose (B)
for 0 (black line), 5 (red), and 15 (blue) min.
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Figure 4.3. Neutralizing the charges at 16th and/or 23rd positions of ZorO impairs the toxicity
of ZorO. (A) Toxicity assay was performed as in Figure 4.1 with either zorO wild type or zorO
E16Q induced by 0.0001% or 0.0005% arabinose. Shown are the mean values ± standard
deviations for three independent cultures. (B) Toxicity assay was performed as in Figure 4.1 with
either zorO wild type or zorO R23L induced by 0.2% arabinose. Shown are the mean values ±
standard deviations for three independent cultures. (C) Toxicity assay was performed as in Figure
4.1 with either zorO wild type or zorO E16Q/R23L induced by 0.2% arabinose. Shown are the
mean values ± standard deviations for three independent cultures.
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Figure 4.4. Reversing the charges at 16th and/or 23rd positions of ZorO impairs the toxicity
of ZorO. (A) Toxicity assay was performed as in Figure 4.1 with either zorO wild type or zorO
E16R induced by 0.2% or 0.005% arabinose. Shown are the mean values ± standard deviations for
three independent cultures. (B) Toxicity assay was performed as in Figure 4.1 with either zorO
wild type or zorO R23E induced by 0.2% or 0.005% arabinose. Shown are the mean values ±
standard deviations for three independent cultures. (C) Toxicity assay was performed as in Figure
4.1 with either zorO wild type or zorO E16R/R23L induced by 0.2% or 0.005% arabinose. Shown
are the mean values ± standard deviations for three independent cultures.
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CHAPTER V

Conclusions and future directions
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The studies presented in this dissertation demonstrate the multiple regulatory mechanisms aimed
at controlling the production of the type I toxin ZorO in E. coli O157: H7 (EHEC). More
specifically, the zorO gene is regulated post-transcriptionally via its 5’ UTR and its corresponding
antitoxin sRNA OrzO.
The 5’ UTR of zorO folds into an extensive secondary structure that sequesters the RBS
limiting zorO translation. Processing of the 5’ UTR exposes a single-stranded EAP region
upstream of the RBS that promotes zorO translation, likely due to allowing ribosome preloading
on the zorO mRNA. Another region spanning +35 to +50 of the 5’ UTR also contributes to zorO
translation and is needed for maximal translation of zorO. While we have not yet elucidated how
the +35 to +50 region promotes translation, we hypothesize that it may increase zorO unfolding or
stabilize the unfolded structure. Our work has not only expanded on the standby model [reviewed
in (1)] but also provides new insights in 5’ UTR mediated regulation: we present the first example
of a 5’ UTR using two independent regions, a standby site and an upstream sequential region, to
modulate translation of a gene. It would be interesting to examine if this additional region is needed
for other genes using the standby model for translation regulation.
Aside from 5’ UTR mediated regulation, the zorO mRNA can be regulated by the sRNA
OrzO through base pairing. The OrzO sRNA base pairs to the 3’ of the EAP region of zorO and
inhibits the zorO translation, likely by interfering with ribosomal interaction with the standby site.
It also stimulates zorO degradation in an RNase III-dependent fashion, hence preventing
accumulation of zorO transcripts. A minimum of 15-nucleotide (nt) of consecutive sequence
complementarity or 17-nt intermittent sequence complementarity is required for successful
repression of the zorO mRNA by the OrzO sRNA. Such extensive base pairing potentials assure
formation of the RNA duplex, which is particularly important given that the RNA chaperone
protein Hfq is not required for the repression of zorO mRNA by the OrzO sRNA.
Why then are so many layers of regulation used to control zorO expression? This may be
partially attributed to the extensive toxicity of ZorO. Our work demonstrated that the ZorO toxin
targets the cell membrane and leads to rapid membrane depolarization. Such toxic effects are at
least in part dependent on the two charged amino acids (Glu at the 16th position and Arg at the 23rd
position) given that mutations of these residues reduce ZorO toxicity. Additionally, we have
conducted metabolomics analyses to determine the potential impacts of zor-orz deletion on EHEC
metabolism (unpublished data). Deletion of the zor-orz locus leads to an overall increase in the
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levels of metabolites detected, particularly of those involved in amino acid or nucleotide
biosynthesis. Given the detrimental effects of the Zor toxins, a delicate control of its production
may be required to assure that ZorO can exert proper function(s) without killing the cells.
The toxic nature of ZorO raises questions about its biological role(s) in EHEC. It is thought
that the type I toxins are involved in bacterial stress responses. In the case of the zorO-orzO locus,
the stress stimulus that induces ZorO production has not yet been identified. Many stress stimuli
that the type I toxin-antitoxin (TA) systems respond to were discovered through identification of
transcriptional factor binding sites around the promoter region of the toxin gene. For example,
both the tisB gene (tisB-istR) and dinQ gene (dinQ-agrB) are repressed by the transcriptional
repressor LexA and are induced in SOS response (2,3). In line with this, we examined the promoter
and its flanking regions of zorO and found several putative transcription factor binding sites. One
is the cAMP receptor protein (CRP) binding site located 67 nts upstream of the zorO transcription
start site. Expression of zorO was decreased in a ∆crp strain, indicative of a role of CRP in the
regulation of zorO (unpublished data). Yet, no significant growth difference was observed between
the EHEC wild type and the ∆zor-orz strain when grown with different carbon sources. Perhaps
growth measurements are not sensitive enough to detect subtle changes caused by altered ZorO
production, especially when taking into consideration the stochastic expression seen in many TA
systems (4). Moreover, it is possible that ZorO protein levels are limited by other unidentified
factors. To examine these possibilities, we are currently constructing zorO transcriptional and
translational fusions using GFP as a reporter. This would allow us to assess the changes of both
zorO mRNA and ZorO protein levels in a more accurate fashion.
An alternative hypothesis is that the type I TA systems possess other functions in addition
to stress response. One interesting observation is that many bacteria harbor multiple different type
I TA loci in the chromosome and some loci can respond to the same stress. For example, the
aforementioned tisB-istR and the dinQ-agrB loci of E. coli are induced upon DNA damage and
both toxins exert their function through targeting the inner membrane, and are seemingly
functionally redundant (3,5). This raises the possibility that each type I locus may have its own
unique function. Indeed, although most type I toxins contain a transmembrane domain and likely
localize within the membrane, loss of membrane integrity is not always the primary effect of the
toxin. For example, the primary effects of the type I toxin Fst or LdrD are on nucleoid segregation
and cell division (6,7); membrane disruption is a secondary effect caused by defects of nucleoid
151

segregation. Work by Göbl et al also suggests that the main function of Fst is to interact with a
specific membrane-bound target rather than disrupting the membrane itself (8). However, the
target of Fst has not yet been identified. We have performed RNA-seq analysis on wild type EHEC
and ∆zor-orz strain to assess the global transcriptional effects of zor-orz (unpublished data).
Comparison of the two transcriptome profiles revealed a series of genes that were differentially
expressed between the two strains. Among those genes, we observed that several involved in
copper homeostasis were upregulated in the Δzor-orz strain. Interestingly, the most highly
upregulated gene copA encodes an ATPase that is known to localize at the inner membrane, leading
to the possibility that ZorO and CopA may interact. A recombinant ZorO protein (1X-FLAG fused
to the C-terminus) will be used to help elucidate not only the localization of ZorO but also potential
binding partners, shedding light on the function of the zorO-orzO locus in EHEC.
In addition to the zorO-orzO, EHEC also harbors another type I gene pair zorP-orzP that
is highly homologous to zorO-orzO (9). Our previous study revealed that there is no cross-talk
between the regulation of these two Zor toxins by the antitoxin Orz sRNAs (10). More specifically,
each Zor toxin is regulated only by its cognate Orz sRNA. Such independent regulation may imply
that these loci participate in distinct cellular processes. One interesting feature of the Zor proteins
is that they differ by one amino acid at the 3rd position (threonine in ZorO and serine in ZorP). If
the type I toxins have additional targets besides the cell membrane as suggested by studies of Fst
(6,8), this different amino acid in the Zor toxins may determine their target specificity. Although
much of the work in this dissertation focuses only on the zorO-orzO pair, it remains a fascinating
area to uncover the function(s) of zorP-orzP in EHEC.
Many other E. coli strains and Shigella species possess zor-orz loci, but some only contain
one gene pair (9). This is not uncommon for type I systems as many exist in various duplicated
copies in bacterial chromosome. For example, E. coli K12 strain has five copies of type I loci ibssib whereas EHEC harbors six (11). Computational analysis suggested that the type I systems
evolve through lineage-specific duplication or deletion (9). Gene duplication and the subsequent
diversification of the duplicated gene are known to be an important mechanism for acquisition of
novel functions in evolution (12). This is well aligned with the notion that different type I loci may
have specific yet undiscovered functions. Phylogenetic analysis of bacterial strains containing
various copies of the same type I pair may provide useful hints on the function and evolution of a
type I system.
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Although it has been over three decades since the discovery of the first type I TA pair, we
are just scratching the surface of characterizing these genetic loci. In addition to the urgent needs
on understanding the functions of these type I systems, questions such as the evolution of the type
I loci remain to be answered.
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